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The incidence and causes of diarrhoea among critically ill patients receiving 
enteral tube feeding were investigated. 
Sixty acutely ill surgical or medical intensive care patients who had had a 
minimum of 48 hrs bowel rest were entered into the study. They were randomly 
assigned to receive one of two lactose free liquid formula diets - "Ensure", a 
commercially available feed containing 825 kCal/L and 34 g/L of protein with an 
osmolality of 441m0sm/1 or "Casilan Oil", a home-made feed containing 840 
kCal /L and 45g/L of protein with an osmolality of 383 mOsm/1. The feeds were 
administered by constant nasogastric infusion. Patients received 1000ml at a 
rate of 40ml per hour for the first day and up to 2000ml at 80 ml per hour for the 
remainder of the study period. 
Investigations included documentation of medical history, medications 
administered and clinical details for each patient. Serum albumin was 
measured and the nutritional status of each patient was assessed using 
anthropometric measurements. Feeds were tested for bacterial contamination 
on the three days following the start of feeding and small intestinal bacterial 
overgrowth was assessed by the 1 g-14c Xylose breath test of Toskes and King. 
Twelve of the sixty patients had to be withdrawn from the trial within 24 hours of 
the start of enteral feeding for medical reasons. The remaining forty eight 
patients completed at least three days on enteral feeding and thereby became 
eligible for analysis. In 10/48 patients (21%) diarrhoea was present before 
enteral feeding began. Four of these 1 O patients continued to pass loose stools 
when enteral feeding was started while the remaining 6 settled. Diarrhoea 
developed in a further 10 patients (21%) after enteral feeding began. The 
overall incidence of diarrhoea in the group of critically ill patients studied was 
therefore 42% (20/48). However, of the fourteen patients who experienced 
diarrhoea during enteral feeding four had diarrhoea before feeding began. 
Therefore, the true incidence of diarrhoea related to enteral feeding was only 
10/38 (26%). Furthermore, in 7 of these 10 patients, another possible cause of 
diarrhoea was present. 
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There was no significant association between diarrhoea and nutritional status, 
hypoalbuminaemia, sepsis, length of bowel rest, sucralfate and antibiotic 
therapy other than amikacin. 
Twenty one patients received Ensure and 27 received Casilan Oil. Despite the 
differences in the composition of the feeds, the incidence of diarrhoea was 
similar on the Ensure and the Casilan Oil. No particular factor pertaining to the 
composition of the feeds was associated with diarrhoea. Significant 
contamination of feeds was universal but there was no constant relationship 
between bacterial counts, or types, and the occurrence of diarrhoea. 
Certain other factors were found to be significantly associated with diarrhoea. 
Abdominal injury was positively associated with the occurrence of diarrhoea 
(p<0.05). Diarrhoea could have been attributed to the underlying disease state 
in 7 of the patients. 
All three patients who were receiving lactulose as treatment for liver failure 
developed diarrhoea. While no association was noted between diarrhoea and 
antibiotic therapy in general, treatment with the antibiotic, amikacin, correlated 
significantly, albeit marginally, with the occurrence of diarrhoea (p<0.05). 
Twenty six patients were tested for small intestinal bacterial overgrowth. Only 
one patient, with an elevated excretion of 14co2, indicative of small intestinal 
bacterial overgrowth, developed diarrhoea. There was, however, a positive 
association between diarrhoea and decreased excretion of 14co2. It would 
appear that the bacterial flora was suppressed in patients with diarrhoea. 
Amikacin therapy was also associated with decreased excretion of 14co2. This 
may suggest that amikacin could have altered the bowel flora with resultant 
development of diarrhoea. 
While abdominal injury and disease were associated with the development of 
diarrhoea and amikacin was a possible factor associated with diarrhoea, the 
results of the present study indicate that enteral tube feeding with either the 
commercial feed, Ensure or the home-made feed, Casilan Oil was not a cause 
of diarrhoea in the majority of critically ill patients assessed. Furthermore, in 
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most patients who commenced the trial with diarrhoea, improvement was noted 
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PEM protein energy malnutrition 
MUAC mid upper arm circumference 
MUMC mid upper muscle circumference 
TPN total parenteral nutrition 
I.C.U intensive care unit 
C.0.A.D chronic obstructive airways disease 
P.T.B pulmonary tuberculosis 
A.R.D.S adult respiratory distress syndrome 
MVA motor vehicle accident 
Ca cancer 
CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1. NUTRITIONAL SUPPORT IN THE CRITICALLY ILL 
1.1. IMPORTANCE OF ADEQUATE NUTRITIONAL SUPPORT 
The management of critically ill patients has been greatly improved during the 
last few decades. One of the most recent advances has been the recognition of 
the importance of adequate nutritional support for this type of patient 
1 . This has 
been due to increasing awareness of the significance of protein and energy 
malnutrition in the acutely ill patient 1 as the presence of malnutrition associated 
with critical illness is known to increase the risk of morbidity and mortality2. 
Protein energy malnutrition has been shown to be common among hospitalized 
patients and in some surveys is reported to be as high as 50%3·4·5·
6. A recent 
study done at Groote Schuur Hospital reported that 30 - 40% of hospitalized 
patients were malnourished7. Some patients enter the hospital in a state of 
malnutrition but others become malnourished during hospitalization. This 
occurs predominantly as a consequence of catabolic stress, surgery and sepsis 
but most disturbing of all, may be due to virtual starvation when patients are 
given only saline or dextrose solutions for prolonged periods2. 
Surgical injury, trauma or critical illness results in an increase in metabolic 
activity 1. Stores of lean body mass can be lost due to protein breakdown and 
alterations in amino acid and carbohydrate metabolism8 as glucose and protein 
have to be used as energy sources. Gluconeogenesis is fuelled by 
endogenous protein breakdown and oxidation. These stores can withstand a 
short period of severe stress but in the case of the malnourished or nutritionally 
depleted patient, serious losses of lean body mass may occur 1. Loss of 
protein, particularly in the musculature involved with respiration, compromises 
pulmonary function and can result in inefficient ventilation9. Efficient wound 
healing and immunocompetence are also dependant on the availability of basic 
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nutrients9, especially in the critically ill patient who is susceptible to infection. 
When associated with critical illness, progressive depletion of body reserves 
increases the possibility of death by sepsis or organ failure 
10. 
The aim of nutritional support during critical illness is primarily to minimise 
excessive loss of body stores and amino acids so that host mechanisms can be 
preserved. The provision of continuous nutritional support is vital to the 
recovery of the patient and when withheld could increase the possibility of 
prolonged sepsis, organ failure and death. 
The question is not whether critically ill patients require nutritional support but 
how their nutritional requirements can be optimally met. 
1.2. CHOICE OF NUTRITIONAL SUPPORT SYSTEM 
Due to the nature of their disease or injury, the majority of critically ill patients 
are unable to ingest food normally for most of the time spent in intensive care. 
The alternatives are to provide either enteral feeding or intravenous parenteral 
nutrition. 
a) Parenteral feeding 
Total parenteral nutrition (f PN) is defined as the administration of nutrients other 
than via the gastrointestinal tract and is usually given to patients when the gut is 
unable to digest and absorb nutrients normally. Parenteral feeding can also be 
used to supplement other forms of nutritional support, especially in severely 
malnourished individuals. The major breakthrough concerning parenteral 
feeding occurred in 1967 and 1968 when Dudrick and Wilmore showed that total 
parenteral nutrition was feasible and effective in dogs, children and adults using 
a central venous line 11 , 12. 
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Complications 
Many complications associated with TPN are potentially life threatening. 
Mechanical complications usually occur during subclavian vein catheterization. 
The most common of these is pneumothorax. Air embolism is a potentially fatal 
complication which may also occur during catheter insertion 13. Catheter sepsis 
is probably the most common complication which occurs during parenteral 
feeding 14. Metabolic complications such as hypo and hyperglycaemia as well 
as electrolyte abnormalities may also occur. 
Parenteral nutrition , either on its own or in conjunction with other forms of 
nutritional support is now widely used to support patients who require 
specialized nutrition. However, due to the high cost of parenteral nutrition as 
well as the associated complications, it has been recommended that the gut 
should be used whenever possible 15. 
b) Enteral feeding 
Enteral feeding is defined as the provision of liquid diets by tube or mouth into 
the gastrointestinal tract 16. 
The practice of providing nutrition by way of an inserted tube is first thought to 
have been used in early Egyptian times when monthly nutrient enemas were 
considered to be essential for health. The first documented case of a patient 
fed directly into the oesophagus by way of a tube dates back to 1598 when 
Cappiveccius is reported to have administered nutrients via a tube attached to 
an animal bladder 15. 
The food or "nutritious liquids" which were given to the patients consisted 
mainly of milk, eggs, broth, meat extracts and invariably a little wine or brandy. 
The feeds were administered in large bolus amounts using what we would 
consider to be a rather barbaric method. The patient was held down and his 
nostrils pinched until he gasped for air. At this point the tube was inserted into 
the mouth and the "nutritious liquids" expressed into the oesophagus. The 
reason for the addition of alcohol now becomes clear! 
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Fortunately this method of providing nutrition was greatly modified and 
improved and by 187 4 softer, more flexible tubes were used and the procedure 
had therefore become slightly less traumatic. Also, naso-oesophageal feeding 
rather than feeding by mouth became more popular during the latter part of the 
19th century. Enteral feeding was widely used to feed patients who refused to 
eat, particularly those in asylums for the insane. In his article on the history of 
enteral feeding, Randall mentions that the deliberate feeding of large quantities 
of liquidised food in order to produce weight gain became more popular in the 
late 19th century when Dr Dubove reported weight gain and significant clinical 
improvement in a group of malnourished patients with tuberculosis. Morison 
also reported improvement in a group of 28 children with diphtheric paralysis of 
the throat, who were given forced enteral feeding 15. 
By the end of the 19th century, tube feeding into the stomach was well 
established. In addition it had been suggested that feeding smaller amounts 
more often decreased the feelings of bloating and epigastric distress 
experienced by patients 15. 
Since the beginning of the 20th century tube feeding has been used as a 
regular procedure in specific diseases 17. Randall remarks that the importance 
of enteral feeding for ill patients, particularly the malnourished, was first 
documented by Parera in 1959 when he emphasised the relationship between 
anorexia and starvation and stressed the importance of nutritional support 
15. 
During the last three decades in particular, major advances and improvements 
have been made to both the method of providing enteral tube feeding and to 
the feeds used. Enteral feeding now forms an integral part of the overall 
treatment of ill patients. It is no longer used only for patients who refuse to eat 
or who need to gain weight, but in addition, is used in any situation where the 
gut is functional but the patient is unable to take food normally. 
Types of enteral feeds 
A wide variety of enteral feeds is now commercially available. In addition to the 
traditional milk based feeds, a number of specialised products exist which are 
designed to meet the specific needs of particular disease groups. These range 
from basic polymeric diets containing whole protein, carbohydrate and fat from 
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sources such as casein, corn starch and oil, to the so-called elemental diets 
which consist of predigested nutrients in the form of glucose complexes, 
crystalline amino acids, protein hydrolysates and fatty acids 
18. Lactose free 
feeds have also become popular due to the incidence of adult lactose 
intolerance. Most of the commercial feeds are in powder form and have to be 
reconstituted using either milk or water. There are a few sterile liquid feeds 
available but these are usually more expensive. Due to the higher cost of 
commercial feeds, home-made feeds consisting of milk, eggs and sugar or a 
variety of specialised ingredients which can be bought commercially, remain 
popular in many institutions. Normal, liquidised food can also be used
17. There 
is , however, evidence to suggest that home-made feeds are associated with 
unacceptable contamination 19 and an increased occurrence of diarrhoea
20. 
At Groote Schuur Hospital the commercially available product, Ensure, is the 
most commonly used enteral feed. It is in powder form and has to be 
reconstituted using water. Another feed, Casilan Oil, which is home made, is 
also popular, and in contrast to the findings of Keighley et a1
20 regarding home-
made feeds, has anecdotally been found to be effective in curtailing diarrhoea 
in patients who cannot tolerate Ensure. This has, however, not been clinically 
proven. 
Feeding techniques 
The time honoured method of bolus feeding up to 200 ml of feed at one time, 
via large bore nasogastric tubes remains the most common method of 
administration of enteral feeds21 . Since 1976, a number of clinicians have 
recommended the use of continuous feeding rather than bolus 
18•22•23. This has 
been mainly due to the development of fine bore feeding tubes and specialised 
feeding pumps. In addition, concern has been expressed about the rate at 
which bolus feeds are administered as gastrointestinal complications are more 
likely to occur when large volumes of feed are administered too quickly
24,25. 
Hiebert et al compared bolus feeding to continuous and found that patients on 
continuous feeding had significantly decreased stool frequency compared to 
those on bolus feeding26. Although there is little evidence to suggest that one 
technique is physiologically superior to the other, studies have shown that 
continuous feeding is superior in terms of nutrient delivery and avoidance of 
side effects 18•27. When continuous feeding is used rather than bolus, the rate 
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of infusion of the feed may be controlled using either specialised infusion 
pumps or the constant gravity drip method where the rate is controlled with the 
use of a roller clamp. 
The first tubes used to provide nutrition enterally consisted of substances such 
as eel skin, silver and indian rubber28. Until the 1950's feeding tubes were stiff 
and large and extremely uncomfortable for patients. With the introduction of 
poly-ethylene and poly-vinyl in the 1950's and 1960's, softer, more flexible tubes 
were developed. Silicone elastomer tubes were first used towards the end of 
the 1960's. During the 1970's polyvinyl was replaced by poly-urethane and 
today the majority of enteral feeding tubes are made from either poly-urethane 
or silicone elastomer. As the tubes are extremely soft and pliable, a guide wire 
is usually necessary for passing such a tube into the stomach. Tubes may vary 
in width from 6 to 18 French. The most popular size for fine bore nasogastric 
feeding is the 8 French but often large bore Ryle's tubes which are 12 to 16 
French are used instead. Although there are no controlled studies which have 
compared large bore to fine bore tubes, the large bore tubes are associated 
with more complications than the fine bore type of tubes
29. Complications 
associated with large bore tubes include gastric erosion, acute sinusitis, 
oesophagitis and nasopharyngeal discomfort to mention a few. Fine bore tubes 
may be easily displaced or misplaced and blockage of viscous feeds may 
occur. Aspiration of feeds is also more common when fine bore tubes are used. 
Feeding via a nasogastric tube remains the most popular route of feeding, but 
feeds are also infused into the jejunum with the use of special long tubes. Direct 
feeding into the stomach or jejunum via gastrostomy or jejunostomy is another 
alternative30. 
In the intensive care units at Groote Schuur Hospital, the enteral feeds are 
infused primarily using the continuous method and the nasogastric route. Wide 
bore (16 French) Ryle's tubes are used in preference to the fine bore tubes due 
to the possible complication of aspiration of feed into the lungs. In addition, oral 




There are relatively few significant complications associated with enteral 
feeding. Potentially the most serious is aspiration of feed into the lungs
31 •3
2. 
Diarrhoea is the most common side effect associated with enteral feeding and 
tube feeding per se has gained a certain notoriety for its tendency to produce 
diarrhoea33,34. Gastrointestinal side effects such as nausea, vomiting and 
abdominal cramps are reported to occur in 1 O - 15% of patients receiving enteral 
tube feeding but are more likely to occur on bolus feeding
34•35•36. Constipation 
is known to occur in patients on long-term enteral nutritional support and this is 
probably due to the low fibre content of most enteral feeds
37. Metabolic 
complications such as hyperglycaemia, dehydration and electrolyte 
abnormalities have been associated with enteral feeding but these are often 
due to inappropriate choice and careless preparation and administration of the 
feed38,39. Although enteral tube feeding is associated with some side effects, 
these are not potentially as serious as the complications which may occur 
during intravenous nutritional support. 
c) Enteral or parenteral? 
Ideally, the provision of adequate nutrition to the hospitalized patient should be 
the responsibility of a team consisting of doctors, dietitians and nurses who 
should make the decisions concerning the type of nutrition and method of 
administration to be used in any particular case40. Patients should be 
continually monitored for signs of intolerance as well as to ascertain the efficacy 
of the nutrition being provided. 
It is widely acknowledged that if there is any function in the gastrointestinal tract, 
it should be used1•16. Animal trials have shown that enteral feeding is as 
effective as intravenous in maintaining or improving nutritional status
41 ,42,43. 
Further animal studies have demonstrated that the intraluminal delivery of 
nutrients is necessary for the maintenance of gastrointestinal integrity
44•45. 
Although only a few studies have been done in humans comparing enteral to 
intravenous feeding, the majority of those done confirm that the nutritional 
requirements of patients with some functioning gut can be met by suitable 
enteral feeding46•47. The cost of enteral nutrition is also considerably lower 
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than that of parenteral nutrition. One day of intravenous feeding costs a 
minimum of R80 compared to R8 per day on enteral feeding. 
Enteral feeding is a safe, cheap method of providing effective nutritional 
support. The major complication associated with enteral feeding is diarrhoea. 
In this study, the effects of enteral feeding, particularly with respect to diarrhoea, 
have been investigated. 
2. DIARRHOEA IN CRITICALLY ILL PATIENTS 
2.1. INTRODUCTION 
Diarrhoea has been defined as an increase in stool frequency and/or volume or 
a decrease in stool consistency29. It is frequently associated with excessive 
faecal water loss caused by either reduced absorption or increased secretion of 
water. 
Diarrhoea is predominantly the result of decreased absorptive capacity of the 
gastrointestinal tract, increased secretion of solute or a combination of 
abnormalities of absorption and secretion. 
When a poorly absorbable substance is ingested, the result is that water is 
drawn into the intestinal lumen. This retention of water could cause an osmotic 
type of diarrhoea. Substances which may cause such diarrhoea include 
osmotic cathartics, magnesium salts such as those used in antacid 
preparations, and lactulose. Carbohydrate malabsorption such as that which 
occurs in lactose intolerant individuals, as well as after extensive intestinal 
resection, may also cause osmotic diarrhoea. 
Secretory diarrhoea occurs when endogenous secretion of solutes such as bile 
acids and fatty acids is increased. This may occur after resection of the distal 
ileum or cholecystectomy. Both bacterial endotoxins and laxitives may cause 
alterations in ion transport and increased secretion of electrolytes. This in turn 
results in passive diffusion of water into the lumen and may cause diarrhoea
48. 
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The absorptive capacity of the gastrointestinal tract is decreased when 
structural damage to the mucosa occurs. lschaemia and inflammatory bowel 
disease, including Crohn's disease and ulcerative colitis could cause such 
damage. 
Acute diarrhoea is one of the most common afflictions known to man. It is, 
however, often difficult to establish the aetiology due to the many possible 
causes of such diarrhoea. 
2.2. INCIDENCE 
Although there are few published articles concerning the incidence of diarrhoea 
among critically ill patients, the impression has arisen that the incidence is high. 
In 1976 Woolfsen et al35 reported that approximately half of a group of 15 
critically ill patients developed diarrhoea. A study done by Kelly et al
31 
demonstrated that 41 % of intensive care patients developed diarrhoea for one 
or more reasons and Brinson and Kolts49 showed a 34% incidence in a group 
of critically ill patients. In a recent study done by Hart and Dobb50, 56% of 
critically ill patients developed diarrhoea. Griebe et al51 however reported that 
only 20 of 112 (17%) patients in intensive care had diarrhoea. The emphasis 
has now been placed on establishing whether a primary cause of this diarrhoea 
exists, and if so, whether it can be identified. 
2.3. FACTORS WHICH COULD INDUCE DIARRHOEA 
a) Disease 
Primary diseases associated with diarrhoea in adults include diseases of the 
gastrointestinal tract such as inflammatory bowel disease, irritable bowel 
syndrome, Crohn's disease, ulcerative colitis, Zollinger Ellison syndrome, acute 
infectious enteritis, intra abdominal abcesses, chronic or acute pancreatitis and 
carcinoma or lymphoma of the bowel51 . The mechanisms whereby diarrhoea 
occurs in these syndromes have been discussed previously. 
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Diarrhoea may also occur in syndromes such as lactose intolerance, tropical or 
non-tropical sprue, viral gastroenteritis, bacterial overgrowth and ischaemia
48. 
Both chronic and intermittent diarrhoea may occur in patients with juvenile onset 
diabetes52 and patients with renal failure may suffer from acute watery 
diarrhoea48. 
Iatrogenic causes of diarrhoea include abdominal surgery such as 
gastrectomy53, ileal resection54 and jejuna! bypass55 as well as radiation 
therapy to the bowel and drug therapy. 
b) Drug therapy 
Drugs commonly associated with diarrhoea include antibiotics, magnesium 
containing antacids, lactulose, corticosteroids, antihypertensive drugs such as 
guanethidine, diuretics, digitalis, quinidine, salicylazosulfapyridine, colchicine, 
biguanides, cholinergic drugs, gold compounds and opiates48. Laxatives are 
obviously associated with diarrhoea. 
Antibiotics and anti-ulcer agents are the most frequently used of the above in 
the treatment of critically ill patients. 
Antibiotics 
Mild diarrhoea is a common adverse reaction associated with antibiotic 
therapy48. Treatment with antibiotics can result in qualitative and quantitative 
alteration of the normal bowel flora56. This may lead to malabsorption of 
nutrients particularly fat and vitamin B 12 and may in turn cause diarrhoea. In 
addition oral antibiotics can directly affect the bowel mucosa and thus disturb 
normal gut function56. 
Pseudomembranous colitis is a potentially serious complication of antibiotic 
therapy. Most forms of antibiotic predispose the gut to the growth of 
Clostridium difficile, the organism which produces the toxin responsible for 
pseudomembranous colitis. Recently some cases of antibiotic-associated 
diarrhoea have been reported to be associated with the cytotoxin of Clostridium 
difficile48•57•58. Lincomycin and clindamycin in particular, were significantly 
associated with pseudomembranous colitis57. 
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Tetracyclines have been shown to most frequently cause diarrhoea
56. Similar 
findings are reported for lincomycin, clindamycin and ampicillin
31 . 
Oral antibiotic therapy is more likely than parenteral to affect both the bowel 
mucosa and the bowel flora56. Studies by Woolfsen et al
35 and Keohane et 
al59 have demonstrated that there is a positive association between oral 
antibiotic therapy and diarrhoea. Kelly et al31 however reported no causal 
relationship between intravenous antibiotic therapy and the incidence of 
diarrhoea. 
A recent editorial in the British Medical Journal suggested that antibiotics be 
considered as a potential cause in all patients who develop diarrhoea
60. 
Anti-ulcer therapy 
Anti-ulcer agents such as H2 receptor antagonists and antacids are often used 
to prevent stress ulceration in critically ill patients31 . The latter comprise a 
variety of substances including sodium bicarbonate, calcium carbonate, 
aluminium hydroxide and magnesium. Side effects associated with the use of 
antacids include sodium overload, hypercalcaemia and phosphate depletion. 
In addition the magnesium containing preparations may lead to severe 
diarrhoea61 . The relationship between anti-ulcer agents and diarrhoea with 
particular regard to bacterial overgrowth will be discussed in the following 
section. 
Lactulose 
Lactulose is an indigestible synthetic disaccharide which is commonly given to 
patients in severe liver failure. The lactulose is converted to lactic acid which 
affects the pH of the intestine. This change in pH affects the bacteria which 




c) Small intestinal bacterial overgrowth 
In healthy humans, the luminal contents of the upper small bowel have a sparse 
microflora population i.e. < 105 organisms/ml. These are primarily gram +ve 
staphylococci, streptococci, lactobacilli and fungi. Coliforms and anaerobic 
organisms rarely occur in the normal small intestine
62·63•64. The mechanisms 
controlling the gut flora population are not clearly understood, but are thought 
to include gastric acid secretion, intestinal motility, mucus products of bacterial 
metabolism and immunoglobulins62. 
When bacterial overgrowth occurs there is a dramatic increase in the 
number of both aerobes and anaerobes present in the ileum and jejunum. 
Small intestinal bacterial overgrowth is most commonly seen in patients with 
surgically produced blind or recirculating loops. This is often referred to as the 
"blind loop syndrome"66. 
Although bacterial overgrowth is most commonly associated with surgically 
constructed blind loops, any factor which results in an alteration in anatomy or 
motility of the small bowel or which kills intraluminal bacteria has the potential to 
cause bacterial overgrowth62. There are factors such as long term ileus and the 
prolonged administration of various forms of medication which, in conjunction 
with bacterial overgrowth, might predispose critically ill patients to diarrhoea
31 . 
In particular, antibiotics, antacids and H2 receptor antagonists may alter the 
normal bowel flora. Antibiotics selectively kill certain strains of bacteria and 
allow others to proliferate. 
H2 receptor antagonist or antacid treatment decreases acid product
ion in the 
stomach, with a resultant increase in pH68. Alteration in pH may affect the 
quantity and quality of the gastrointestinal flora69 and has been associated with 
overgrowth of bacteria in the small intestine67. Treatment with the H2 receptor 
antagonist, cimetidine, in particular, has been associated with both small 
intestinal bacterial overgrowth70 and with diarrhoea31,67. 
Bacterial overgrowth in the small intestine is known to affect fat absorption. In 
the presence of bacterial overgrowth, fat malabsorption occurs primarily due to 
altered bile salt metabolism62. 
The effect of bacterial overgrowth on carbohydrate absorption is not 
established. Toskes and King showed that diminished urinary xylose excretion 
after an oral xylose excretion test in the rat blind loop syndrome was due to the 
bacterial catabolism of xylose to carbon dioxide
71 . Similar studies in humans 
have revealed a significantly increased catabolism of 
14C-d-xylose to 14co2 in 
patients with bacterial overgrowth72. Indeed this forms the basis of one of the 
tests used for identifying small intestinal bacterial overgrowth. lntraluminal 
fermentation of carbohydrate is thought to occur, as increased levels of volatile 
short chain fatty acids have been measured in the presence of overgrowth
73. 
Investigations with the blind loop rat model have shown a decreased in vitro 
uptake of monosaccharides and a decreased in vivo absorption
74•75. 
Increased flux of protein across the mucosa into the lumen has been a 
consistent finding in both the rat model and occasionally in humans with the 
blind loop syndrome77•78. Increased urinary excretion of indicans and phenols 
has been used as a test for detecting the presence of bacterial overgrowth 7
6. 
In summary, malabsorption of nutrients is known to occur in the small bowel in 
the presence of bacterial overgrowth and can result in diarrhoea. 
d) Bowel rest, sepsis and shock 
The majority of patients in intensive care have experienced severe shock due to 
either surgery, trauma or sepsis. The ileus associated with the above 
conditions results in a period of bowel rest. Periods of fasting are known to 
result in a decrease in both villous height and cell proliferation in animal 
models 13, and long term bowel rest is known to cause villous atrophy of the 
gastrointestinal tract in man 79•80. Even when complete nutritional support is 
provided intravenously, structural and functional atrophy may occur8
1,82,83 with 
decreased secretions of enzymes such as sucrase, maltase, lactase and 
galactokinase81 •84. Commencement of feeding in this situation could therefore 
result in malabsorption and diarrhoea. 
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e) Infectious diarrhoea 
Infection with intestinal pathogens such as salmonella, shigella, campylobacter 
and escherichia coli species can induce diarrhoea in critically ill patients. 
Consequently, stools should always be sent for culture
31 ,58. 
f) Protein Energy Malnutrition 
Protein energy malnutrition (PEM) and kwashiorkor in children, have been 
associated with atrophy of the intestinal villi85·86. In primates in whom PEM has 
been experimentally induced, structural changes of the small intestine have 
been reported87. Studies in man have also demonstrated an alteration in gut 
structure in the presence of PEM88-91 . For example, Tandon et al reported 
blunting of the villi and inflammatory cell infiltration in the majority of a group of 
malnourished individuals. Following treatment with a high protein diet these 
mucosal abnormalities improved progressively89. Platt and co-workers have 
demonstrated that pigs fed diets markedly low in protein, developed mucosal 
atrophy and diarrhoea92. 
Pancreatic function is reduced in children with kwashiorkor and marasmus and 
can lead to maldigestion93. In addition, O'Keefe et al have shown reduced 
pancreatic enzyme secretion and synthesis in an adult patient with severe 
malnutrition94. 
Protein deficiency in adults can therefore lead to intestinal alterations such as 
flattening of the villi and decreased secretion of digestive enzymes
95,96. Such 
changes in gut structure and function could clearly predispose to malabsorption 
and diarrhoea. 
g) Vitamin A deficiency 
Probably the most recent factor which has been implicated in the aetiology of 
diarrhoea in critically ill patients, is vitamin A deficiency. Lack of vitamin A has 
been shown to predispose burn patients to the development of diarrhoea
97·98. 
Vitamin A deficiency can cause changes in the metabolism of epithelial tissues 
and can therefore cause thinning of the gut epithelium and loss of mucous 
secretion99• 1 °0. A relationship between vitamin A deficiency and diarrhoea has 
been previously suggested in children 101.102. 
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h) Hypoalbuminaemia 
One of the more recent publications concerning causes of diarrhoea in critically 
ill patients was that by Brinson et al49. It was reported that hypoalbuminaemia 
i.e. a serum albumin concentration of less than 26g/L was invariably associated 
with the occurrence of diarrhoea. A previous study by Cobb et al demonstrated 
that serum albumin levels of less than 30 g/L significantly correlated with the 
development of diarrhoea at the start of feeding 103. 
Hypoalbuminaemia is thought to have the potential to cause diarrhoea due to 
intravascular volume expansion, which is the result of a reduction in plasma 
oncotic pressure. This, in turn, is caused by malnutrition, protein loss or 
haemodilution by excessive fluid infusions49. Volume expansion on its own has 
caused diarrhoea in experimental animals104. Hypoalbuminaemia in ICU 
patients is common and results from shifts in fluid balance and fluid space 
losses rather than malnutrition. 
i) Enteral feeding 
Results of various studies attempting to establish an association between 
diarrhoea and enteral tube feeding, are varied and contradictory. Woolfsen et 
al35, Peaston34 and Broom and Jones65 reported a low incidence of tube feed 
related diarrhoea among critically ill patients receiving specially designed home-
made feeds. Kelly et al31 and Brinson and Kolts49 have, however, reported a 
strong positive association between enteral tube feeding and the occurrence of 
diarrhoea. In the latter studies, 67% of the patients who were receiving the 
commercially available enteral solutions developed diarrhoea. The most recent 
publication concerning diarrhoea and tube feeding is that by Gottschlich et al
97. 
The authors suggest that incidence of diarrhoea on enteral feeding may vary 
depending on the amount of fat present in the enteral feeds. 
There are a number of factors related to enteral feeding which could cause 
diarrhoea. Properties of the feed itself such as significant bacterial 
contamination 1o5•106, high lactose content33• 107, excessive amounts of 
fat 1oa,109 and high osmolality 110-111 · 112 have all been associated with 
diarrhoea. In addition conditions of administration such as feeds given at very 
low temperatures65• 114 or rapid infusion rates 115 have been shown to be 
possible causes of diarrhoea. 
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Bacterial contamination 
Food carries certain strains of bacteria which are harmless but if food infected 
with pathogenic organisms is ingested, harmful side effects including diarrhoea 
may occur. The accepted level of contamination by bacteria of non-sterile food 
is 100 colony forming units/ml (cfu/ml) and it is recommended that food 
containing more that 200 cfu/ml should be rejected
116. Similar criteria are 
applied to reconstituted enteral feeds. Certain bacteria such as Escherichia 
coli, Salmonella, Staphylococcus aureus, Clostridium spp and Klebsiella 
should not be present in reconstituted tube feeds 116. Most of these organisms 
occur normally in the body, particularly in the nasal passages and the large 
intestine 117. Contamination of feeds by these organisms is therefore often 
indicative of poor hygiene. 
Contamination may occur at any stage of preparation or administration, and the 
composition of enteral feeds is such that micro-organisms grow luxuriantly if 
introduced into the fluid. Particular factors associated with contamination of 
enteral feeds are mixers and liquidisers, contaminated working surfaces and 
probably most important of all, contaminated staff118. Bastow et al
119 have 
shown that diets blended in the diet kitchen are more likely to become 
contaminated. 
Many studies have demonstrated that bacterial contamination of enteral feeds is 
common 105, 120-124. Anderton 118 reported contamination of both hospital and 
commercial feeds to exceed 109cfu/ml. Casewell 123 reported that a large 
proportion of feeds given to patients in intensive care were contaminated with 
up to 8 x 106 cfu/ml. The most common organisms found in the various feeds 
investigated in these studies were Klebsiella, Enterobacter, Acinetobacter and 
Bacillus species. Sixty eight per cent of feeds were found to contain Klebsiella 
species in the study conducted by Casewell123. While not usually implicated in 
diarrhoea, Kelly remarks that Pottecher is of the opinion that Gram-negative 
bacteria cause diarrhoea in critically ill patients31 . In the study by Anderson et 
a1105, an association was noted between the extent of contamination and the 
incidence of diarrhoea although contamination was not invariably associated 
with diarrhoea. In the same study, other possible causes of the diarrhoea were 
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not investigated and contamination cannot therefore be cited as the only 
possible cause. 
Casewell et al124 have reported a case of septicaemia resulting from bacterial 
contamination of a tube feed but in general, bacterial contamination has not 
been associated with serious clinical complications 
106. Concern has however 
been expressed over the possible role of nasogastric feeds as potential 
sources of cross infection, especially in patients in intensive care 
123. There has 
also been speculation that contaminated feeds with bacterial counts as low as 
1 o4 cfu/ml can cause colonisation of the digestive tract and that this could result 
in infection by organisms such as E.coli, Klebsiella and Pseudomonas species. 
Critically ill patients treated with antibiotics, steroids and immunosuppresive 
agents might be prone to this type of infection 106. 
Contamination of enteral feeds remains a problem, especially as in the majority 
of state financed hospitals, non-sterile feeding systems are used due to the cost 
of the commercially available sterile systems. However, although contamination 
of enteral feeds has been associated with diarrhoea, there is no clear-cut 
evidence to suggest that this is a cause and effect relationship. 
Lactose 
A considerable proportion of healthy adults is intolerant of the carbohydrate, 
lactose, due to a deficiency of the enzyme, jejunal beta-galactosidase which is 
responsible for the digestion of lactose to glucose and galactose 
125. Lactose 
cannot be absorbed intact and when jejunal beta- galactosidase is not present, 
the unabsorbed lactose remains in the gut lumen. The presence of the lactose 
causes an increase in osmotic pressure and fluid is drawn into the lumen. This 
in turn results in increased transit rate of the bowel contents and, commonly, 
diarrhoea. Bacteria also ferment the lactose in the large intestine to lactic acid, 
fatty acid, hydrogen and methane and this further exacerbates the 
symptoms 126. 
Asian, African and Jewish population groups are particularly prone to 
maldigestion of lactose 127. O'Keefe et al have reported a very high incidence of 
lactose intolerance among black South Africans125•128. One study reported that 
90% of a random group of South African Zulus had abnormal lactose tolerance 
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tests 128. Walike and Walike reported that 60% of Black Americans are lactase 
deficient129. Lactose intolerance is relatively uncommon among Caucasians 
and occurs in approximately 6% of the European population 
130. Six to 20% of 
white Americans are reported to be intolerant of lactose 
129. The effect of acute 
illness and malnutrition on gastrointestinal absorption and digestion is largely 
unknown. Mucosa! jejunal beta-galactosidase activity may be temporarily 
depressed and the result would be decreased lactose digestion
131 •132. 
Malnutrition, intestinal resection, radiation enteritis and infectious diarrhoea may 
reduce the lactase content of the bowel92. 
Initially, many tube feeds were milk-based and therefore contained significant 
quantities of lactose. It has been suggested by Hindmarsh and Clark 
107 that 
lactose could have been a cause of the diarrhoea associated with a 
jejunostomy feed used by Masterton, Dudley and Macrae 
134. In addition 
O'Keefe et al have shown that lactose containing liquid formulae were poorly 
tolerated by malnourished black African patients whereas lactose free formulae 
were well tolerated135. Walike and Walike reported that 87% of patients given a 
large lactose load such as that typically found in milk-based formulae, 
developed diarrhoea 129. Consequently, a number of lactose free enteral feeds 
are now commercially available. 
Fat 
The use of low fat diets for patients who are prone to developing diarrhoea has 
been reported136•137. Anderson et al137 reported a significant decrease in 
diarrhoea in a group of patients with Crohn's disease when given a low fat diet. 
In another study, burned guinea pigs were fed on either a low fat diet (i.e. fat = 
30% of nonprotein calories) or a high fat diet (i.e. fat = 50% of nonprotein 
calories). Significantly more in the group on the 50% diet, developed 
diarrhoea 136. Gottschlich et al demonstrated that a low fat diet (13.5 g/1) was 
associated with a 16% probability of diarrhoea, compared to a 62% probability 
on a feed with a fat content of 33 g/1, in a group of burns patients 
138. The 
results of a recently published article by Gottschlich et al substantiate these 
findings as less gastrointestinal intolerance was noted on a low fat regime (13 
g/1)97. It is difficult to ascertain from the data presented in the latter study what 
the effect was on the incidence of diarrhoea when the feeds containing 
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intermediate amounts of fat were used. It is also notable that the other feeds 
used in this study contained unusually high proportions of fat (i.e. 65 - 80 g/1). 
Fat maldigestion is known to occur when pancreatic enzyme digestion is 
significantly reduced. This is commonly seen in patients with acute or chronic 
pancreatitis and can result in an osmotic type of diarrhoea97. In addition, 
gastric surgery may delay the release of lipase and prevent adequate mixing of 
the lipase with the bowel contents29. 
Where patients do not have pancreatic insufficiency, another mechanism 
whereby a high fat diet could cause diarrhoea has been suggested97. 
Prostaglandins are known to affect bowel motility 140• 141 and intestinal ion and 
water secretion 142• 143 and increased levels could therefore induce diarrhoea. 
The fatty acids esters of arachidonic and linoleic acids, found predominantly in 
vegetable oils, are precursors in the biosynthesis of prostaglandins. One can 
but speculate as to whether prostaglandin overproduction, following intake of 
large amounts of such oils, may be a factor in diarrhoea. 
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Osmolality 
A hypertonic solution delivered directly into the small bowel may cause passive 
diffusion of water into the intestinal mucosa and therefore cause diarrhoea
29. 
High osmolality has been implicated as a cause of diarrhoea in enterally fed 
patients 133,134. The introduction of full strength hypertonic formulae at the start 
of feeding in particular, was considered to be the major reason for the 
diarrhoea 144,145,146. Consequently, "starter regimens" were introduced. For 
the first 3 - 5 days of feeding patients were given feeds which had been diluted 
to quarter or half strength. The osmolality was then gradually increased until full 
strength was tolerated. 
The value of "starter regimens" in avoiding gastrointestinal side effects remains 
a controversial issue. Recent studies have shown that such regimens are 
unnecessary and result in poor nutritional intake. Feeds should, however, be 
given as a constant infusion rather than in bolus amounts. Keohane et al 
reported that administration of a hypertonic, polymeric enteral feed ( < 430 
mOsm/1) to patients with normal gastrointestinal function, was not associated 
with diarrhoea59. Rees et al reported similar results using an elemental diet 
(630 mOsm/1) given to patients with impaired gastrointestinal function 
147. 
Zarling et al showed that enteral feeds with osmolalities varying between 325 
and 690 mOsm/1 were well tolerated by healthy individuals 
148. Ruppin et al 
examined potential side effects of hypertonicity of enteral diets and concluded 
that osmolality was not a cause of gastrointestinal side effects 
149. 
It has therefore been recommended that the use of starter regimens be 
abandoned when elemental as well as polymeric diets are used, provided 
administration is continuous rather than intermittent59, 11 a. 111 . 
Case et al have demonstrated that rapid equilibration of dietary osmolality 
occurs in the stomach and duodenum in healthy individuals and it is suggested 
that differences in absorption rates of diets with different osmolalities are a 
function of the carbohydrate source in the diet rather than the direct effect of the 
osmolality 112. 
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Temperature of the feed 
It has been recommended that feeds should be given at room temperature as 
the bolus administration of a cold feed can produce abdominal cramps and 
diarrhoea65• 110,1 14. Prewarming of feeds is, however, not recommended due to 
the increased risk of bacterial contamination 118. If continuous drip feeding is 
used, the refrigerated feed should attain room temperature within a short time. 
Administration of the feed 
Before the introduction of fine bore feeding tubes, bolus feeding of 200 - 600 ml, 
4 - 8 times a day, was the accepted method. Recent surveys done in the U.S.A 
continue to indicate that many patients receiving enteral nutrition still receive 
bolus type feeding usually given in less than 20 minutes per feed115. Bolus 
feeding can cause rapid and uncontrolled emptying into the small bowel and 
can therefore induce diarrhoea33•36, 144. The use of fine bore feeding tubes and 
infusion pumps makes it possible to feed patients at a continuous rate. The 
result is that the change in osmotic load is not as great, and the likelihood of 
diarrhoea occurring is reduced. Studies by Woolfsen et a135, Dobbie and 
Butterick 150, McHugh and Moran36 and Hiebert et al26 have provided clear 
evidence in favour of the continuous feeding method compared to the bolus 
method. In a study by Heitkemper et al115, normal volunteers experienced 
more abdominal discomfort and nausea when feeds were administered at fast 
infusion rates and the larger feeding volumes significantly affected the time 
taken for gut motility to return to normal. Although Jones et al151 reported that 
more than 85% of patients were fed successfully by simple gravity infusion, 
feeding pumps facilitate the maintenance of a constant rate of infusion. 
Carefully controlled conditions of administration of feeds should minimise the 
risks of side effects associated with enteral feeding. 
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CHAPTER2 
RATIONALE FOR AND OBJECTIVES OF THIS STUDY 
RATIONALE 
Adequate nutrition is of vital importance in the care of critically ill patients. 
Diarrhoea in such patients can result in malabsorption of vital nutrients and fluid, 
and exacerbate an already critical situation. 
As mentioned before, there are few published articles concerning diarrhoea in 
critically ill patients. The results of these studies are varied and contrasting, 
especially in relation to the possible association between enteral feeding and 
diarrhoea. In particular, controversy exists relating to the differences between 
home-made and commercial feeds and their effect on diarrhoea. 
It should be noted that the studies mentioned above have been done over a 
period of twenty years. During this time there have been numerous advances 
made with regard to enteral feeding techniques and types of feeds as well as to 
the overall treatment of critically ill patients. Therefore, in view of the large 
number of variable factors associated with these studies, it is not possible to 
draw any clear-cut conclusion from the available literature as to whether the 
diarrhoea is due to the "tube feeding" itself, whether choice of feed and method 
of administration are important factors or whether there are other more 
important causes which are unrelated to enteral feeding. 
The prevalence and common causes of diarrhoea among critically patients have 
not been previously investigated at Groote Schuur Hospital. However, clinical 
experience has led medical and nursing staff at this hospital to believe that the 
prevalence is high, especially among patients receiving enteral nutrition. 
Enteral feeding has aquired a reputation for being the most probable cause of 
the diarrhoea. Consequently, enteral nutritional support is either substantially 
reduced or temporarily stopped when diarrhoea occurs. Sometimes total 
parenteral nutrition is introduced instead but frequently patients do not receive 
optimum nutritional support for a number of days. In addition, initiation of 
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enteral feeding is often delayed when patients already have diarrhoea as the 
feeding is assumed to exacerbate the situation. It is a cause for concern that 
enteral nutritional support is delayed, withdrawn or reduced in the event of 
diarrhoea occurring when it has not been unequivocally established that the 
enteral feeding is the only possible cause of the diarrhoea. 
OBJECTIVES 
On the basis of this rationale it was decided to: 
(1) investigate the prevalence of diarrhoea in critically ill patients 
(2) examine the possible association between the prevalence of diarrhoea 
and enteral feeding 
(3) establish whether choice of enteral feed affected the prevalence of 
diarrhoea by comparing a home-made feed (Casilan Oil) to a commercial 
feed (Ensure) 
(3) examine whether there was an association between any of the other 
factors outlined above and the incidence of diarrhoea. 
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CHAPTER 3 
PATIENTS AND METHODS 
1. PATIENT SELECTION AND MONITORING 
All patients commencing tube feeding in both the surgical and the respiratory 
intensive care units were considered for inclusion in the trial. Patients who had 
diarrhoea at the time the feeding was commenced were not excluded as it was 
important to ascertain whether enteral feeding affected the severity of diarrhoea. 
There were, however, certain criteria which had to be met: 
a) Patients had to have had a minimum of 48 hrs bowel rest with or without 
total parenteral nutrition (TPN), prior to the commencement of enteral 
feeding. This period was chosen so that nutrients taken orally prior to 
the commencement of the trial could be excluded as a cause of 
diarrhoea. 
b) Enteral feeding would only be commenced with the permission of the 
doctor in charge and would be withdrawn if necessary according to 
his/her advice. 
c) The route of feeding had to be nasogastric rather than via gastrostomy or 
jejunostomy. Feeds were to be administered at a constant rate of 
infusion. 
d) No other form of enteral nutrition except the enteral feed was to be 
administered during the trial period. 
e) In the final analysis only patients who had been enterally tube fed for a 
minimum of three days would be included. Three days was chosen as 
the minimum period so that tolerance of up to 2000ml of feed per 24 
hours could be assessed. 
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Prior to commencement of trial, note was made of the following: 
a) A detailed medical history 
b) All medication: type, dose and frequency received by the patient for two 
weeks prior to the start of trial. 
c) Type of nutrition received and length of bowel rest before 
commencement of enteral feeding. 
d) Overall condition of the patient including presence of sepsis in 
association with pyrexia. Patients were considered septic if either blood, 
sputum or wound cultures were found to be positive. 
e) Presence and severity of diarrhoea if present before enteral feeding. 
The following were also measured in order to estimate nutritional status: 
a) The concentrations of serum albumin, iron, zinc and magnesium. 
b) Triceps skinfold thickness and mid upper muscle circumference(MUMC). 
Patients 
Sixty patients fulfilled the requirements for inclusion in this study. However, 
enteral feeding was withdrawn in twelve of these patients within 24 hours of 
commencement. The feeding was stopped at the request of the doctor-in-
charge due to medical reasons such as sudden deterioration in clinical 
condition necessitating a change to TPN, or rapid improvement in clinical 
condition necessitating a change to an oral diet and transfer from the intensive 
care unit. The remaining forty eight patients completed the minimum three days 
of enteral feeding. Fifteen of these 48 patients were females and 23 were males. 
Seventeen were white, 19 coloured and 12 black. The ages varied from 18 to 84 
years and the mean age was 47.5 ± 17.9 years. The mean length of time on 
enteral feeding was 10.2 ± 11. 7 days (range 3 to 56 days). Twenty nine patients 
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had received treatment in the surgical intensive care and 19 in the respiratory 
intensive care. A summary of the clinical diagnoses of the patients studied is 
shown in Table 3.1. Details for each patient may be found in Appendix 1 and 
details of diagnosis, clinical condition and medication administered may be 
found in Appendix 2. 





Liver failure 3 
Gastrointestinal 6 
Abdominal aortic aneurism 5 
Neurological 1 
Burns 1 
2. FEEDS AND FEEDING METHODS 
(a) Choice of feeds 
Two feeds were chosen for comparison. As a result of the controversy 
surrounding home-made versus commercial feeds and their association with 
diarrhoea as well as the untested reputation of Casilan Oil in curtailing 
diarrhoea, it was decided to compare Ensure (commercial) to Casilan Oil 
(home-made). 
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b) Composition and preparation of feeds 
Ensure (Abbott Laboratories, Johannesburg, South Africa), a commercially 
available, lactose free feed, has been the primary source of enteral nutrition in 
our intensive care units for some time. The home made feed, Casilan Oil, was 
designed at Groote Schuur Hospital. It contains Casilan powder (Glaxo 
Laboratories, South Africa) as the protein source, Sunflower oil as the fat source 
and Caloreen powder (Roussel Laboratories, South Africa) as the carbohydrate 
source. Multivitamin syrup (Lennon Ltd, Cape Town, South Africa), iron in the 
form of ferrous gluconate (Fisons Pharmaceuticals, Chloorkop, South Africa), 
magnesium in the form of magnesium glycerophosphate (Labethica, 
Bethlehem, South Africa), zinc in the form of zinc sulphate (Groote Schuur 
Hospital, Cape Town, South Africa), sodium as sodium chloride (Sabax, 
Johannesburg, South Africa) and potassium as potassium chloride(Labethica, 
Bethlehem, South Africa) were also added to the Casilan Oil. 
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Table 3.2 shows the comparative composition of the two feeds. 
Table 3.2: NUTRITIONAL ANALYSIS OF ENSURE AND CASI LAN OIL 
Ensure Casilan oil 
Type of feed Commercial Home-made 
Total kcal/L(non N) 825 840 
Protein content(g/L) 34 45 
N content(g/L) 5.3 7.2 
CHO Content(g/L) 131 120 
Fat content(g/L) 34 40 
Magnesium(mmol/L) 197 190 
Zinc(mg/L) 15 15 
lron(mg/L) 9 9 
Lactose content(g/L) 0 0 
Osmolality(mOsm/L) 441 383 
Protein Source soya protein and casein casein 
Fat Source corn oil sunflower oil 
CHO Source corn starch glucose 
polymers 
kcal= kilocalories, N = nitrogen, non N = non nitrogen, CHO= carbohydrate 
Both feeds are lactose free. In both the protein source is primarily casein and 
vegetable oil is the source of fat. Casilan Oil contains slightly more fat than 
Ensure. 
Casilan Oil has a lower osmolality than Ensure primarily because the 
carbohydrate source consists of glucose polymers rather than simple glucose. 
The only other major difference between the feeds is that Casilan Oil has a 
higher protein content. 
The recommended daily intake of protein for hypercatabolic critically ill patients 
is 2.25 g/kg/day which is equivalent to 135 g/day for an individual weighing 60 
kg. This is far in excess of the 68 g/day that would be provided by 2000ml of 
Ensure or even the 90g/day provided by 2000ml of Casilan Oil. Protein would 
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have to be added to both these feeds so that the nutritional requirements of 
critically ill patients may be optimally met. 
There were two reasons why the quantity of enteral feed given was not 
according to estimated requirement levels. It has been the policy of the I.C.U to 
start enterally fed patients on 1000 ml of feed/24 hours and to slowly increase 
this to 2000 ml/ 24 hours, depending on tolerance. For the purposes of this 
study, we did not change the method used except that patients were given 2000 
ml/ 24 hours by the second or third day after commencement of feeding rather 
than increased strength of feed over a prolonged period. Secondly, it was 
primarily tolerance to the feed which we wanted to evaluate, and all patients 
were therefore prescribed equivalent concentrations and volumes. 
The feeds were reconstituted in the diet kitchen during the morning of the day 
on which they were to be administered. The solutions were mixed in a liquidiser 
using a non sterile technique and tap water. The solutions were then decanted 
into 1000ml glass bottles which were transported to the wards and refrigerated 
until required. The first bottle of feed was started approximately 4 hours after 
reconstitution. The feed was therefore cold to begin with but soon equilibrated 
to room temperature. 
(c) Technique of administration 
All the patients were fed continuously using wide bore Ryle's tubes (16 French). 
In the majority of cases, the infusion rate was controlled using an infusion pump. 
The initial rate of infusion was approximately 40 ml per hour and this was 
increased to 80 ml per hour when the feed was increased to 2000ml per day. 
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The mean amount of feed administered on the three days to the group who 
developed diarrhoea after commencement of feeding and the group who did 
not, is documented in Table 3.3 below. 
















Patients who fulfilled the criteria for inclusion were randomised to receive either 
Ensure or Casilan Oil starting on 1000ml full strength feed for the first 24 hrs. 
This was increased from day 2 onwards according to the patient's fluid 
requirements. Twenty seven patients received Ensure and 21 received Casilan 
Oil. 
(a) Assessment of tolerance to enteral feed 
Tolerance was assessed mainly by the presence or absence of diarrhoea. 
However, other symptoms of intolerance such as vomiting or abdominal 
distension were also noted if present. Diarrhoea was defined as mild ( < 3 loose 
stools per day), moderate (3 - 5 loose stools per day) and severe (greater than 
5 loose stools per day). If patients developed severe diarrhoea, they were 
crossed over to receive the alternative feed. 
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(b) Assessment of clinical condition 
During the study note was made concerning medication administered and 
overall medical condition of the patient. In addition, serum levels of albumin 
were measured every day. In patients who had diarrhoea stool samples were 
cultured to test for the presence of infectious organisms. Samples of the feeds 
were examined for contamination on each day of the trial. Small intestinal 
bacterial overgrowth was tested for in twenty six of the patients on the third day 
after commencement of enteral feeding, using the 1g 14c xylose breath test66. 
4. METHODS 
(a) Estimation of nutritional status 
The methods of Blackburn and Thornton 165 were used for assessment of 
anthropometric measurements. All anthropometric measurements were taken 
by the author, ensuring good reproducibility. Each measurement was taken 
three times and the final result obtained by averaging the two closest values. 
Triceps skinfold thickness 
Fat stores were estimated by measurement of the triceps skinfold thickness. 
Triceps skinfold thickness is a measure of the patient's subcutaneous fat stores 
and is considered to be a good index of overall body fatness 152. The 
measurement was made using Harpenden calipers. The width of a fold of skin 
on the triceps muscle halfway between the acromial process of the scapula and 
the olecranon process of the ulna is measured. By comparing the measurement 
to standard values it is possible to calculate the "percentage of normal". In this 
way fat stores can be estimated. 
Mid upper arm circumference (MUAC) 
The mid upper arm circumference is the circumference of the upper arm at the 
same point at which the triceps skinfold thickness is measured. 
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Mid upper muscle circumference (MUMC) 
Mid upper muscle circumference gives an estimation of muscle size and is 
calculated using the triceps skinfold and MUAC measurements in the formula: 
MUMC(cm) = MUAC(cm) - (3.14 x triceps skinfold thickness(cm)) 
The value obtained is then compared to standard values 153. 
Weight was not measured as in addition to being extremely difficult to obtain a 
weight measurement in these critically ill patients most of whom are intubated 
and heavily sedated, the results are often not accurate due to the fluctuations in 
fluid balance which commonly occur. 
Serum levels of iron, zinc and magnesium were obtained as part of the 
nutritional assessment. 
(b) Bacteriology 
Feed samples were tested for bacterial contamination for the first three days of 
feeding, approximately 24 hrs after reconstitution. Samples were taken from the 
bottle while the feed was being administered to the patient. The rubber stopper 
of the bottle was wiped with an alcohol swab and samples were drawn into 
sterile syringes. These were then immediately taken to the Bacteriology 
laboratory for culturing as follows. Sterile 1 ml pipettes were used to transfer 
samples. 0.1 ml of the feed sample was plated onto 4% blood agar. Another 
0.1 ml sample was mixed with 9.9 ml sterile Difeo Nutrient Broth (D.N.B) to 
facilitate counting. 0.1 ml of this solution was also plated onto 4% blood agar. 
The remainder of the feed sample was then centrifuged, the supernatant 
discarded and the deposit plated onto 2% blood agar in a Mcconkey plate to 
test for gram -ve single colonies. All plates were then incubated overnight 
before organisms were identified and reported as colony forming units(cfu)/ml. 
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(c) Small intestinal bacterial overgrowth 
Detection 
The conventional method of detecting bacterial overgrowth is by bacteriologic 
culture from jejuna! aspirates61 •62. However in addition to being an invasive 
procedure, the collection and culture of specimens is complicated and time 
consuming. 
A number of alternative methods are available for evaluation of bacterial 
overgrowth. Urinary indican excretion has been used to test for the presence of 
bacterial overgrowth 154 but can neither accurately identify the site of 
overgrowth nor differentiate between bacterial overgrowth and other 
malabsorption disorders61 . Several other diagnostic procedures have been 
evaluated. These methods rely on metabolism by the bacteria of ingested 
substrates such as 14c labelled bile acids 155, 14C-d-xylose 156 or 
carbohydrate 157. The measurement at timed intervals of the breath excretion of 
labelled 14c carbon dioxide or hydrogen liberated from the substrate by the 
bacteria gives an indication of the presence and concentration of the bacteria. 
The 14C-d-xylose method used by Toskes and King has been shown to be the 
most sensitive and specific of those mentioned above and is a reliable test for 
detection of small bowel bacterial overgrowth66•158,159. In the normal healthy 
person a test dose of 14c xylose would be absorbed intact in the jejunum and 
be excreted unchanged in the urine as it cannot be metabolised by man. In the 
presence of small intestinal bacterial overgrowth, however, the 14c xylose is 
metabolised. Oxidation results in the production of 14c carbon dioxide and 
water which are absorbed into the bloodstream. The 14c carbon dioxide is 
then excreted in expired breath. Consequently, detection of 14c-labelled 
carbon dioxide in the breath provides an indirect measure of bacterial 
overgrowth. It is, however, important to note that the small bowel is not entirely 
sterile and contains a light bacterial growth. Therefore, even in the normal 
individual, a small amount of 14c xylose is oxidised to 14c carbon dioxide. An 
increase in excretion of 14c carbon dioxide would indicate bacterial overgrowth 
whereas reduced excretion of label could represent either abnormally 
suppressed bacterial flora or reduced intestinal motility. 
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A modified version of the method used by Toskes and King 156 was used in the 
present study. 5µ.Ci of labelled xylose was given rather than the 10µCi used by 
Toskes and King as this dose was found to yield sufficient 14co2 for 
reproducible measurements. The dose has the added advantage of halving the 
radiation exposure. The length of time for which patients were fasted was less 
than the usual 10 hrs as they were receiving continuous drip feeding. The 
infusion of enteral feed was stopped 4 hours before the ingestion of the xylose. 
Preparation of dose 
In order to minimize the possibility of bacterial contamination, a solution of 
labelled xylose was made by mixing 500 ml of sterile water with 250µ Ci of 14c-
xylose(Amersham, U.K)). This was then divided into 10 ml aliquots which were 
bottled and stored at -16 C until required. The 10ml of labelled solution was 
thawed prior to the test and mixed with 1 g of non-labelled d-xylose (Saarchem 
Pty Ltd, Muldersdrift, South Africa). 
Clinical Method 
Sixty ml of distilled water was added to the labelled solution and this mixture 
was then given as a bolus to the patient, via the nasogastric tube and flushed 
down the tube with a further 60ml of water. Breath samples were collected in 2L 
douglas bags before the test and at half hour intervals for 3 hours following 
ingestion of the xylose. These were taken either directly from the patient or if 
the patient was receiving ventilatory support, from the expiratory port of the 
ventilator. One mmol of CO2 was trapped by bubbling the breath sample into a 
solution containing 1 mmol hyamine hydroxide(Packard Instruments, 
Groningen, Netherlands) and phenolphthalein indicator(Merck, Darmstadt, 
Germany). Ten ml scintillation mixture (lnstagel, Packard Instrument Co, 
Downer's Grove, Illinois, U.S.A) was then added and the activity (expressed as 
dpm (disintegrations per minute)) of the mixture was measured by liquid 
scintillation counting using the Tri-carb 1500 liquid scintillation counter (Packard 
Instrument Co, Downer's Grove, lllinois,U.S.A). The activity measured by the 
counter gives an indication of the proportion of orally ingested 14C xylose 
expired as 14C02 per mmol CO2. 
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Calculation of results 
The pre-dose dpm measurement was taken as a baseline background count 
and was therefore subtracted from the total dpm obtained for the subsequent 
samples. Results were calculated according to the formula: 
% of ingested 14c xylose 
excreted as 14co2 = 
dpm in 1 mmol expired CO2 
~~~~~~~~~~~ x100 
dpm in 5µ Ci 14C-xylose 
and the percentages plotted against time. 
( d) Stool cultures 
Stool samples were tested for the presence of pathogens such as shigella and 
salmonella using a FPC (Fecal Parasite Concentrator) (Evergreen Scientific, 
U.S.A). 
5. ANALYSIS OF DATA 
Data was analysed using an IBM AT computer. A database (DBASE 111) was 
used for most of the analysis. A statistical package (EPIST AT) was used for 
statistical analysis. 
The CHI-square test was used to assess the significance of differences in the 
relative frequencies of discrete variables. This test was used to assess the 
significance of the difference between the number in the group who had 
diarrhoea compared to the number in the group who did not, concerning the 
various factors possibly associated with diarrhoea. As the number of patients in 
this study was small, if the number of patients was less than 5 in any cell, the 
Fisher's exact test was used instead of the CHI- square. 
The unpaired Student's t-test was used to assess the significance of differences 
between the means in groups when a certain parameter was measured for each 




1. INCIDENCE OF DIARRHOEA 
Forty eight patients completed at least three days on enteral feeding and 
thereby became eligible for analysis. Of these 48, 1 O patients had had 
diarrhoea before the commencement of enteral feeding and 1 O developed 
diarrhoea after enteral feeding was started. The incidence of diarrhoea either 
with or without enteral feeding was therefore 42% (20/48). Diarrhoea continued 
in four of the ten patients who had passed loose stools before enteral feeding 
and settled in the remaining six just after commencement of feeding. Fourteen 
patients had diarrhoea whilst receiving enteral feeding. However, as four of 
these patients had had diarrhoea before feeding was started, a true reflection of 
incidence of diarrhoea related to enteral feeding would be attained by excluding 
the entire group of ten patients who had had diarrhoea before the start of 
enteral feeding. Diarrhoea could therefore have been attributed to enteral 

















Fig.4.1 Incidence of diarrhoea before and after enteral feeding (d = diarrhoea) 
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2. ANALYSIS OF TOLERANCE 
(a) Diarrhoea before feeding 
Of the 1 O patients who had had diarrhoea before enteral feeding commenced, 5 
patients had mild diarrhoea and 5 had moderate diarrhoea. In 6 of these 
patients, the diarrhoea resolved within 24 to 48 hours of the commencement of 
feeding. The remaining 4 patients continued having diarrhoea of the same 









Fig. 4.2 Follow-up of diarrhoea after commencement of enteral feeding in patients who 
had had diarrhoea before. (Imp = improved) 
(b) Diarrhoea after feeding 
Of the group of 1 O patients who developed diarrhoea after commencement of 












Fig 4.3. Severity of diarrhoea experienced by patients who developed diarrhoea after 
commencement of enteral feeding. (mod = moderate, sev = severe). 
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Four of these patients experienced only one episode of mild diarrhoea on the 
third day after enteral feeding had started and none thereafter. Five patients 
developed mild to moderate diarrhoea within 48 hours of commencement of 
feeding which continued for at least three days before improving and 1 patient 
developed severe diarrhoea ( > 8 loose stools per day) which continued for one 
week. 
(c) Other side effects 
Concerning other side effects, 2 patients who had no diarrhoea developed 
abdominal distension, and two patients who had diarrhoea also had an episode 
of vomiting. 
(d) Additional observations 
No significant difference was noted in the mean age of the group of 20 who had 
diarrhoea compared to the group of 28 who did not. The mean age for the non-
diarrhoea group was 4 7 .3 ± 17 .6 years and for the diarrhoea group, 48.8 ± 18. 7 
years. Table 4.1 shows that race did not correlate with the occurrence of 
diarrhoea but that significantly more females had diarrhoea than males. In 
addition, significantly more patients who had diarrhoea (85%) were in the 
surgical intensive care units than in the respiratory I.C.U's (p < 0.05). 
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Table 4.1 Relationship of race,sex and type of I.C.U to occurrence of diarrhoea 
Diarrhoea No diarrhoea p 
(n = 20) (n = 28) 
Males 10 23 0.04 
Females 10 5 (CHl
2) 
Whites 8 9 0.76 
Coloureds 8 11 (CHl
2) 
Blacks 4 8 
Surgical ICU 17 15 0.049 
Respiratory ICU 3 13 (F.E) 
F.E = Fisher's Exact test 
3. POSSIBLE CAUSES OF DIARRHOEA 
All the patients who had diarrhoea, either before or after the commencement of 
enteral feeding, were investigated as to the possible causes of the diarrhoea. 
a) Disease 
Details of primary diagnoses and clinical features of the patients are given in 
Appendix 2. Of the 20 patients who had diarrhoea either before or during the 
study period, the diarrhoea which developed could have been due to disease 
in 6 patients. Patients 9 and 20 had undergone gastrectomies just prior to 
going on the trial. Patient 1 had had a colectomy. Patient 11, who developed 
severe diarrhoea at the start of feeding, had bowel ischaemia after abdominal 
and chest trauma. Patient 12 had acute haemmorrhagic pancreatitis. Patient 13 
had developed an abdominal abscess. 
Fifteen of the 20 patients who had diarrhoea had experienced some form of 
abdominal injury, including surgery, compared to 11 of the 28 who had no 
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diarrhoea. Abdominal injury due to either trauma or surgery significantly 
correlated with the occurrence of diarrhoea (p = 0.03). 
b) Factors relating to clinical condition 
Table 4.2 summarises the data pertaining to clinical factors in the aetiology of 
diarrhoea. 
Table 4.2. Clinical factors and occurrence of diarrhoea 
Diarrhoea No diarrhoea Total p 
(n = 20) (n = 28) (n =48) 
Sepsis 10 16 26 0.84(CHl
2) 
Albumin < 26g/l 5 4 9 0.57(F.E) 
Lngth BR> 7 days 2 1 3 0.37(F.E) 
Lngth BR = days of bowel rest prior to feeding, F.E = Fisher's Exact test 
None of the above factors significantly correlated with the occurrence of 
diarrhoea. In addition none of the stools tested contained pathogenic 
organisms. Uremia was not present in any of the patients with diarrhoea. 
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c) Nutritional status 
Table 4.3 summarizes the anthropometric and trace element measurements. 
The Student's t-test was used to compare the means of the values measured in 
the two groups. 
Table 4.3. Nutritional status versus occurrence of diarrhoea 
Diarrhoea No diarrhoea p 
%ideal MUMC 96.1± 13.5 97.5± 16.1 0.9 
% ideal triceps 70.6t23.0 84.2±48.6 0.4 
Zinc(mmol/L) 10.9± 5.0 11.2± 2.8 0.1 
n (8.4 - 22.9) 
Mg(mmol/L) 0.79± 0.2 0.87± 0.2 0.8 
n (0.7-1) 
lron(mmol/L) 9.10± 7.1 5.00± 4.3 0.2 
n (8 - 30) 
Mg = magnesium, n = normal range 
Nutritional status was similar in the two groups. There were no patients who 
were severely nutritionally depleted. Serum levels of zinc and magnesium were 
within normal ranges in the majority of patients but serum iron levels were lower 
than normal in the group of patient who did not have diarrhoea. 
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d) Medication 
Details of medication administered to the patients may be found in Appendix 2. 
Antibiotics 
Table 4.4 is a list of the most commonly administered antibiotics and their 
association with the occurrence of diarrhoea. Most of the antibiotics were 
intravenously administered. 
Table 4.4 Relationship of antibiotic treatment to occurrence of diarrhoea 
Diarrhoea No diarrhoea Total p 
(n == 20) (n ==28) (n == 48) 
General 16 25 41 0.63 CHl
2 
*Amikacin 14 10 24 0.04CHl
2 
Flagyl 6 9 15 0.87CHl
2 
PenG 7 7 14 0.67CHl
2 
Cloxacillin 2 6 8 0.26 F.E 
* = p < 0.05 
F.E = Fisher's Exact test 
Although antibiotic treatment in general was not related to diarrhoea, treatment 
with the antibiotic, amikacin (500 mg/ day i. v) was significantly associated with 
the occurrence of diarrhoea (p<0.05). The validity of this significance was, 
however, questioned. In view of the association noted between diarrhoea and 
abdominal injury, the correlation between abdominal injury and amikacin was 
examined. 
48 
Of the total of 48 patients studied, 32 had either abdominal injury or amikacin or 
both. Fifty five per cent (18/32) of patients who had one or other or both of the 
above, had diarrhoea. In contrast only 12,5% (2/16) of patients who had neither 
abdominal injury or amikacin, developed diarrhoea (Table 4.5). 
Table 4.5 Association between amikacin therapy, abdominal trauma and the occurrence 
of diarrhoea. 
Diarrhoea No diarrhoea 
+amikacin 
+abd. injury 11 6 
+amikacin 
-abd. injury 3 4 
-amikacin 
+abd. injury 4 4 
-amikacin 
-abd. injury 2 14 
abd. trauma = abdominal trauma 
Of the twenty patients with diarrhoea, 4 had abdominal injury alone and 3 had 
amikacin alone whereas 11 had both abdominal injury and amikacin. The 
occurrence of diarrhoea differed significantly in the group who had both 
amikacin and abdominal injury compared to those who had either amikacin (p = 
0.009) or abdominal injury (p = 0.024). This would suggest that the combination 
of the two factors increased the occurrence of diarrhoea, but that it is not 
possible to determine which was of greater significance. 
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Anti-ulcer therapy 
Table 4.6 lists the number of patients who received agents for the prevention of 
stress ulceration. 
Table 4.6 Agents used to prevent stress ulcers 
Anti-ulcer drug Diarrhoea No diarrhoea Total 
Sucralfate 
Ranitidine 
No anti-ulcer drug 












Oral sucralfate (1g QID) (Continental Ethicals, Cape Town, South Africa) was 
used in twenty one patients and the H2 receptor antagonist, ranitidine (50mg 
1.V) (Glaxo, Wadeville, South Africa) in four. 
The use of sucralfate or ranitidine was not positively associated with diarrhoea 
(p = 0.45). 
Lactulose 
Three patients (patients 4,8 and 14) were given lactulose as treatment for liver 
failure. All three had diarrhoea. 
e) Small intestinal bacterial overgrowth 
Twenty six patients were tested for the presence of small intestinal bacterial 
overgrowth using the 14c xylose test. 
14c xylose excretion results obtained for the I.C.U patients in this study were 
compared to those previously obtained in our laboratory in normal control 
subjects and in patients with known bacterial overgrowth 160. The results 
obtained for these patients were similar to those of Toskes and King for 
comparable groups 156. 
50 
In the following graphs relating to the results of the xylose breath test, the 
percentage of ingested 14c xylose expired as 14co2 is plotted against time 
after ingestion. The Student's t-test was used to assess the significance of 
differences. 
Only one patient excreted significantly more 14co2 than controls, indicative of 
bacterial overgrowth. This patient developed mild diarrhoea within 24 hours of 
the start of enteral feeding. After three days on enteral feeding the patient was 
given a normal ward diet as he had been extubated and could eat normally. 
The mild diarrhoea, however, continued. 
Fig. 4.4 illustrates that the patient's curve of excretion of 14co2 over the three 
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Fig. 4.4 Metabolism of C xylose in patient with positive 
bacterial overgrowth 
Fig 4.5 illustrates that the entire group of 26 patients studied excreted 
significantly less 14co2 than controls. All of these patients were receiving or 
had recently received some form of antibiotic therapy. 
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Fig. 4.5 Metabolism of C xylose in critically ill patients (Mean ± S.D) 
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The effect of various factors on the metabolism of 14c xylose was then 
investigated. 
The results of the bacterial overgrowth studies with particular reference to the 
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0 30 60 90 120 150 180 
TIME (Minutes) 
p < 0.05 vs No diarrhoea 
* p < 0.001 vs controls 
Fig 4.6 Metabolism of
14 
C xylose in patients with and without 
diarrhoea (Mean + S.D) 
Patients who had diarrhoea when the 14c xylose test was done, excreted 
significantly lower amounts of 14co2 than those who had no diarrhoea at the 
time of the test. 
In view of the association between amikacin therapy and the occurrence of 
diarrhoea (Table 4.4) and the possible association between antibiotic therapy 
and alteration of the bowel flora we investigated the effect of amikacin on the 
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Fig 4. 7 Metabolism of C xylose in patients receiving amikacin therapy 
(Mean ± S.D) 
Patients who were rece1v1ng amikacin therapy at the time of the bacterial 
overgrowth test excreted significantly lower amounts of 14co2 than patients 
who had not been on amikacin (p< 0.05). 14co2 excretion in the group who 
had not received amikacin therapy was similar to that found in controls. The 
group of patients who had received amikacin in the period prior to the study 
excreted intermediate amounts of 14co2. 
Further analysis of the bacterial overgrowth test with regard to anti-ulcer 
therapy showed that there was no significant difference in the excretion of 
14co2 between patients who received treatment with sucralfate and those who 






























-A- Bacterial overgrowth 
· · ·• · · Sucralfate (n = 12) 
/ 











.. .. ... 
.. ,·······--~ ~ 0.002 x- -- -.-;.-;.--·.!-·..:.·...:- -- - -
- - - X :-: :-. -: :-: :": :-. • ..... . 
...,-.-r·····• 
0 
0 30 60 90 120 150 180 
TIME (Minutes) 
14 
Fig 4.8. Relationship between metabolism of C xylose and sucralfate therapy 
(Mean ± S.D) 
g) Enteral feeding 
Diarrhoea developed in 1 O of the 48 patients when enteral feeding was 
commenced. Factors other than enteral feeding could, however, have caused 
the diarrhoea in seven of the ten. Patient 20 had had had a gastrectomy, 
patient 11 had severe ischaemia, patient 12 had acute pancreatitis, patient 14 
had been receiving lactulose as treatment for liver failure, patient 19 tested 
positive for bacterial overgrowth, patient 13 had an abdominal abscess and 
patient 18 had suffered severe abdominal trauma. No direct cause could be 
found for the mild diarrhoea which developed in the remaining three patients. 
The choice of feeds and method of administration used for this study eliminated 
lactose intolerance, hyperosmolality, fat, and temperature of the feed as 
potential causes of diarrhoea. 
Type of feed 
Table 4. 7 lists the number of patients who received Ensure or Casilan Oil. 
Diarrhoea was as common in patients who received Ensure as in those who 
received Casilan Oil(p = 0.89). 
















All samples of the feeds given to patients in this study contained more that 2 x 
1 o5 cfu/ml. This is far in excess of the 200 cfu/ml which is the maximum 
acceptable in reconstituted enteral feeds 116. However, as every patient did not 
develop diarrhoea when given the contaminated feed, contamination was not 
directly associated with diarrhoea. 
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Table 4.8 is a comparison of the various organisms which were cultured in the 
feed samples taken from both the diarrhoea group and the n.on-diarrhoea 
group. The numbers given represent the percentage of patients in each group 
who received a feed during the study period which contained the particular 
organism. The CHI-square test was used to assess the significance of 
differences. 
Table 4.8 Frequency of occurrence of organisms in the feed samples 






































Alpha strep = alpha haemolytic streptococcus, Staph epi = staphylococcus epidermidis, E 
coli = escherichia coli, Staph aureus = staphylococcus aureus, sp = species 
There was no significant difference in the type of organisms found in the 
samples of feeds given to the patients who had diarrhoea compared to those 
who did not. In addition there was no difference in the degree of contamination 
between the Ensure and the Casilan Oil. 
No factor relating to the composition of the feeds was significantly associated 
with diarrhoea. 
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4. TREATMENT OF DIARRHOEA 
Only one patient (patient 11) developed severe diarrhoea while on enteral 
feeding. This patient was commenced on enteral feeding with Casilan Oil. The 
feed was changed to Ensure after 48 hours but the diarrhoea continued as 
before for a further two days. Enteral feeding was then discontinued for 24 
hours and the patient was treated with codeine phosphate (30g orally, 6 
hourly). The diarrhoea improved and enteral feeding was successfully re-
introduced. 
Patient 12, who had severe acute pancreatitis had moderate diarrhoea on both 
Ensure and Casilan Oil, but when a special low fat feed containing medium 
chain triglycerides was introduced, the diarrhoea improved. 
No other patients were crossed over to the alternative feed. The mild to 
moderate diarrhoea which developed at the start of enteral feeding in the 
remaining eight patients improved within two to five days without any 
intervention. 
5. EFFECT OF DIARRHOEA ON LENGTH OF STAY IN ICU AND OUTCOME 
The length of time spent in I.C.U by the diarrhoea and non-diarrhoea groups is 
compared in Table 4.9. 
Table 4.9 Effect of diarrhoea on length of stay in intensive care unit 
With diarrhoea No diarrhoea 
(n = 20) (n = 28) 
(m± S.D) (m± S.D) 
Days in I.C.U 13.9± 7.8 19.4± 14.0 
Range 5-34 4-60 
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The presence of diarrhoea either before or after the start of enteral feeding did 
not significantly affect length of stay in intensive care. 
Table 4.1 O shows the relationship between diarrhoea and the clinical condition 
of the patients on completion of trial. 
Table 4.10. Outcome versus presence of diarrhoea 
Diarrhoea No diarrhoea p 
(n = 20) (n = 28) 
Condition improved 9 {45%) 18 {64%) 0.30 CHl
2 
Condition unchanged 6(30%) 7 {25%) 0.97 CHl
2 
Condition worse 1 {5%) 0 {0%) 0.41 
Died 4 {20%) 3 {11%) 0.26 F.E 
F.E = Fisher's Exact test 





Previous authors have investigated the incidence of diarrhoea among critically 
ill patients31 ,35,49,50. In the present study, 20 of the 48 (42%) patients who were 
investigated had diarrhoea, with or without enteral feeding. The incidence of 
diarrhoea among critically ill patients studied was therefore similar to that 
reported in previous, albeit not comparable, studies. 
If one examines the incidence of diarrhoea related to enteral feeding in 
particular, of the 20 patients who experienced diarrhoea, ten had had diarrhoea 
before the commencement of feeding and ten developed diarrhoea after feeding 
was started. Of the ten who had had diarrhoea before , six settled on enteral 
feeding and the diarrhoea persisted in the remaining four. Although fourteen 
patients experienced diarrhoea whilst on enteral feeding, a true reflection of 
incidence of diarrhoea related to enteral feeding may be obtained by excluding 
the 1 O patients who had had diarrhoea before. Diarrhoea may therefore have 
been associated with enteral feeding in 26% (10/38) of patients. It is, however, 
important that the diarrhoea which developed in these 1 O patients could have 
been caused by factors other than enteral feeding in 7 of the 10. The 
occurrence of diarrhoea among patients receiving enteral feeding was lower 
than that reported in recent studies by Kelly et al31 , Brinson and Kolts49 and 
Gottschlich et al97 but similar to that found in the earlier studies by Peaston34, 
Broome and Jones65 and Woolfsen et al35. It is however notable that the 
number of patients investigated is small in both the present study and the earlier 
studies. In contrast, the recent studies utilised far larger groups of patients. 
This may account for the differences in the prevalence of diarrhoea. 
There is considerable controversy concerning the incidence of diarrhoea as 
related to the type of enteral feed used, in particular, home-made versus 
commercial. In the present study, we have compared a home-made feed 
(Casilan Oil) to a commercial feed (Ensure). The composition of the Ensure and 
Casilan Oil differed with respect to osmolality, carbohydrate source and fat 
content. As osmotic pressure is affected mainly by the type and quantity of 
carbohydrate as well as the electrolytes in a feed, Silk et al139 have 
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recommended the use of glucose polymers in enteral feeds so that the calories 
may be increased without increasing the osmolality. The home made feed used 
in this study is similar to the one used in a study done by Woolfsen et al35 as 
both contained glucose polymers as the carbohydrate source and caloreen as 
the protein source. The home-made feed used in the study by Broome and 
Jones65 also contained glucose polymers as the source of carbohydrate. The 
incidence of tube feed related diarrhoea was low in both these studies and 
similar to that found in the present study. The use of glucose polymers and the 
resultant lower osmolality of the Casilan Oil was, however, not associated with a 
lower incidence of diarrhoea than that noted in patients who received Ensure, 
where the carbohydrate source was corn starch. Glucose polymers would 
nevertheless be useful if the calories of a feed had to be increased without 
increasing the osmolality. 
Casilan Oil contained slightly more fat (40g/l) than Ensure (34g/1). Although 
Gottschlich et al reported that 62% of patients developed diarrhoea when given 
a feed containing 33g fat/1138, we found that 34 - 40 g fat per litre of feed was 
tolerated by the majority of patients on enteral feeding. The diarrhoea which 
developed in patient 12, who had acute pancreatitis, could have been 
precipitated by the fat in the feed as improvement was noted when the patient 
was given a special low fat diet, containing medium chain triglycerides. 
Bacterial contamination of the feeds was universal and bacterial counts 
exceeded 2 x 105 cfu/ml in every sample analysed. A wide variety of organisms 
was identified. However, there was no direct association between bacterial 
contamination or the types of bacteria and the incidence of diarrhoea. It has 
been reported that contamination is more likely in home-made feeds 19. We 
have, however, found the degree of contamination to be similar in the Ensure 
and Casilan Oil. 
Although bacterial contamination was not significantly associated with the 
occurrence of diarrhoea, it is a cause for concern that such high levels of 
contamination were present in our enteral feeds. Enteral administration of 
contaminated feeds with possible side effects such as septicaemia 124, cross 
infection 123 or colonization of the gastrointestinal tract 106 should be avoided at 
all costs, particularly in critically ill patients who are more prone to developing 
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infection. It is therefore recommended that the possible source/s of the 
contamination should be isolated by testing samples of the feed at various 
stages of preparation and administration. 
In spite of the differences in composition between the Ensure and the Casilan 
Oil, there was no significant difference in the occurrence of diarrhoea on the two 
feeds. The anecdotal reputation of Casilan Oil as a cure for diarrhoea is 
therefore not substantiated by the present data. 
Home-made feeds were administered in the studies by Peaston34 , Broome and 
Jones65 and Woolfsen et a135 in which low incidences of tube-feed related 
diarrhoea were reported. Commercially available products were used in the 
later studies done by Kelly et al31 , Brinson and Kolts49 and Gottschlich et al97 
who reported higher incidences. The only controlled study in which a home-
made feed was compared to a commercial feed is that by Keighley et a120. The 
authors reported an increased occurrence of diarrhoea in patients receiving a 
"home-brew" compared to those who were given a commercial preparation. 
Unfortunately, details of possible causes of diarrhoea other than disease and 
enteral feeding were not investigated. In addition the feeds used differed to 
those used in the present study. 
No particular factor pertaining to the composition of either of the feeds was 
significantly associated with diarrhoea. Our findings support the view that 
"starter regimens" are unnecessary as the majority of patients included in the 
present study tolerated 1000ml full strength feed at the commencement of 
feeding. In the ten patients who had had diarrhoea before feeding was 
commenced, the diarrhoea did not worsen when enteral feeding was started. 
On the contrary, a marked improvement was noted in six of the ten shortly after 
feeding was commenced. 
Disease could have been a direct cause of diarrhoea in seven of the patients. 
In addition, abdominal injury was found to be positively associated with 
diarrhoea. A possible explanation for this association could be based on the 
hypothesis that shock causes diversion of blood flow from the intestinal mucosa 
and results in failure to absorb sodium and water from the colon as well as 
changes to bile acid metabolism 161 . This may in turn induce diarrhoea. The 
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association between abdominal injury and diarrhoea may have a bearing on 
the higher occurrence of diarrhoea noted in the surgical intensive care units. 
The question of a possible association between abdominal injury and diarrhoea 
has not been investigated in previous studies. There was no obvious clinical 
cause for the diarrhoea in only three of the patients who developed diarrhoea 
while on enteral feeding (Patients 15, 16 and 17). 
Diarrhoea is a well known side effect of certain drugs. One such drug is 
lactulose and indeed all three patients with liver failure who were receiving 
lactulose, developed diarrhoea. Antibiotic therapy has been frequently 
associated with diarrhoea35,56,57,58,59 and this applies particularly to 
lincomycin and clindamycin57. In the present study, no association was noted 
between diarrhoea and intravenous antibiotic therapy in general. However, 
treatment with the antibiotic, amikacin, showed significant, albeit marginal, 
correlation with the occurrence of diarrhoea. Amikacin is a semi-synthetic 
aminoglycoside and is not a recognised cause of diarrhoea. It is more 
commonly associated with side effects such as ototoxicity and nephrotoxicity. 
As amikacin is a relatively new antibiotic there are few publications referring to 
its use concerning diarrhoea in critically ill patients. Amikacin was, however, 
given to patients in the study conducted by Gottschlich et al97. While these 
authors did not find an association between any specific antibiotic and the 
occurrence of diarrhoea their data showed that no less than nine of the twelve 
patients who were receiving amikacin developed diarrhoea. The possibility that 
the association found between amikacin and the occurrence of diarrhoea was a 
spurious one related to abdominal injury was examined. It would appear from 
the data that while both amikacin and abdominal injury are related to diarrhoea, 
it is not possible to determine which may be of greater importance. 
There has been speculation concerning the possibility that small intestinal 
bacterial overgrowth may be a significant cause of diarrhoea in critically ill 
patients 161 . This possibility has not been previously investigated. In the 
present study, the 14c xylose test of Toskes and King 156 was used as an index 
of small intestinal bacterial overgrowth. On this basis, only one of the twenty six 
patients tested had bacterial overgrowth. This particular patient had diarrhoea. 
In contrast, the metabolism of 14c xylose was significantly lower in the entire 
group of patients tested when compared with results in a control group. In 
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addition, patients who had diarrhoea at the time of the 14c xylose test excreted 
significantly lower amounts of 14co2 than those who did not have diarrhoea. 
This would strongly suggest that the bacterial flora of the small intestine was 
significantly depressed in those patients with diarrhoea. 
Antibiotics are thought to disturb the normal flora of the gut and this is assumed 
to lead to small intestinal bacterial overgrowth56. Analysis of the results of the 
14c xylose tests in the present study suggested that the converse in fact 
occurred. The possibility of decreased gut motility cannot be excluded as a 
possible cause of the decreased metabolism of xylose, but this is unlikely as 
diarrhoea is usually associated with increased gut motility. Excretion of 14co2 
was significantly lower in the group of patients who were receiving amikacin at 
the time of the test when compared to patients who had not received this 
antibiotic. In addition, patients who had been on amikacin just prior to the test, 
excreted intermediate amounts of 14co2. The effect of amikacin on the bowel 
flora is not surprising in view of the broad spectrum activity of this drug against 
organisms such as Pseudomonas, Escherichia coli, Klebsiella sp, Salmonella 
and Staphylococcus aureus. Our results also suggest that the bacterial 
population in the small bowel approaches normality when the amikacin therapy 
is discontinued. The data in the present study have shown a correlation 
between the incidence of diarrhoea and treatment with amikacin. In addition, 
decreased metabolism of 14c xylose, which is indicative of a decreased 
bacterial population, also correlated with both diarrhoea and amikacin therapy. 
This suggests that the diarrhoea may be related to the alteration in the bacterial 
flora produced by this antibiotic. The mechanisms whereby reduced bacterial 
flora in the small intestine could cause diarrhoea have not been defined. Silk et 
al have ,however, speculated that the combination of enteral feeding and 
antibiotic therapy might predispose to diarrhoea 162. The proposed rationale is 
based on the role of short chain fatty acids (SCFA) in colonic absorption. 
SCFA's are known to be powerful stimulants of colonic water and electrolyte 
absorption. These fatty acids are normally produced in the colon as a result of 
the metabolism by bacteria of unabsorbed carbohydrate and fibre. Certain 
antibiotics have been shown to inhibit SCFA production (unpublished 
observations of Silk et al). It is therefore speculated that the combination of 
reduced colonic carbohydrate associated with the low fibre content of enteral 
feeds, and the inhibition of bacterial fermentation by antibiotics, may cause 
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decreased production of SCFA. This in turn may affect colonic absorption of 
water and electrolytes and possibly cause diarrhoea. 
The prophylactic use of anti-ulcer drugs in the treatment of stress ulceration in 
critically ill patients is now commonplace. The H2 receptor antagonists increase 
the pH of the gastric contents by reducing acid output. The resultant increase in 
pH may cause bacterial overgrowth and diarrhoea70. Indeed, treatment with 
the H2 receptor antagonist, cimetidine, has been associated 
with 
diarrhoea31 •67. The anti-ulcer agent , sucralfate, acts by coating the gastric 
mucosa rather than by affecting acid output. Previous studies have reported 
that sucralfate neither causes a significant increase in the pH nor promotes the 
growth of bacteria in gastric juice68. In the present study it has been shown that 
sucralfate was not positively associated with the occurrence of diarrhoea. In 
addition, results of the 14c xylose test showed that sucralfate had no significant 
effect on the bacterial flora of the small intestine. 
The present study does not allow any conclusions to be drawn on the possible 
effect of H2 receptor antagonist therapy on small intestinal bacterial flora. 
Our findings regarding hypoalbuminaemia as a cause of diarrhoea, are contrary 
to those of Brinson and Kolts49 and Cobb et a1103. We could find no 
association between diarrhoea and a serum albumin of less than 26 g/1. This 
may have a bearing on the type of feeds used in this study as more recent 
studies have suggested that the diarrhoea associated with hypoalbuminaemia 
may be induced by the elemental nature of the feed163. Use of diets with higher 
concentrations of peptides has been shown to eliminate the diarrhoea 
associated with a low serum albumin 164. 
The methods used for assessment of nutritional status in the present study were 
not ideal. However, as no good markers exist at present for the measurement 
of nutritional status in critically ill patients, it is extremely difficult to assess the 
status of such patients accurately. The traditional tests such as measurement 
of serum levels of albumin and transferrin, delayed cutaneous hypersensitivity 
and even anthropometric measurements such as weight, triceps skinfold 
thickness and mid upper muscle circumference, are of limited use in the critical 
care situation as most of these parameters are influenced by changing 
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metabolic status and fluid compartments 164. Bearing this in mind, measurement 
of triceps skinfold thickness and muscle circumference does give an indication 
of fat and muscle stores and these parameters were therefore used in this 
study. 
According to our criteria, none of the patients studied was severely 
malnourished. Nutritional status was similar in the two groups and the majority 
of patients were within the normal ranges for both fat and muscle stores. This 
is to be expected as most of the patients admitted to intensive care are victims 
of trauma or sudden severe illness and their nutritional status is therefore 
usually good. However, the importance of providing adequate nutritional 
support cannot be over-emphasised as protein loss must be minimised. It is not 
ideal to provide nutritional support without measuring the patient's nutritional 
requirements and calculating the amount and type of feed which will meet these 
requirements. However, the scope of this study is such that it was not possible 
to examine the full nutritional adequacy of the feeds. 
The presence of mild to moderate diarrhoea did not significantly affect the 
length of time spent in intensive care or the mortality rate. It is therefore 
perhaps more advantageous to the patient to have mild diarrhoea for 2 or 3 
days than to be deprived of nutritional support. 
It is extremely difficult to predict whether or not a particular patient will develop 
diarrhoea. Our results indicate that females are more prone than males to 
developing diarrhoea. The reason for this is not known. Patients who have 
experienced severe abdominal injury might be predisposed to diarrhoea. 
Gastrointestinal liver disease, pancreatic insufficiency and medication cannot be 
excluded as possible factors in the aetiology of diarrhoea in critically ill patients. 
It is important that when diarrhoea does occur, all the possible related factors 
must be carefully analysed. The data presented have shown that disease, 
abdominal injury and medication may be associated with the occurrence of 
diarrhoea. A particularly important finding was that suppression of the intestinal 
bacterial flora rather than proliferation was associated with diarrhoea and that 
such bacterial suppression could be attributed to amikacin therapy. In contrast, 
no association could be demonstrated between diarrhoea and enteral feeding 
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with either home-made or commercially available feeds. This finding may be 
due to the selection of feeds and the carefully controlled conditions of 
administration. Since enteral feeding has been shown to accelerate wound 
healing, restore cell- mediated immunity and improve nitrogen balance 
15, the 
correct and careful application of this nutritional support technique should 




The study emphasises the multifactorial origin of diarrhoea in critically ill 
patients. An important conclusion is that no particular factor relating to the 
composition of the enteral tube feeds was associated with the development of 
diarrhoea. In addition, the implementation of enteral feeding did not worsen the 
diarrhoea in patients who had had diarrhoea previously. On the contrary, in the 
majority of these patients, the diarrhoea improved soon after enteral feeding 
was started. 
The results suggest that the common policy of stopping enteral feeding when 
patients develop diarrhoea in intensive care be deferred, if possible, while other 
reasons for the diarrhoea are investigated. The best approach would be to 
continue enteral feeding unless the diarrhoea becomes unmanageable. Should 
this occur, enteral feeding may be temporarily stopped and intravenous feeding 
commenced. Enteral feeding should be re-introduced as soon as possible with 
careful monitoring of tolerance. 
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Pt.No ICU Age Race sex Lngth B.R Diarr Diarr. Days Amik. sucral. Abd.t outcome 
(yrs) (days) bef. aft. feeding 
1* Surg 70 w M 4 +mild - 10 y y y Imp 
2 Surg 54 w M 3 +mild - 3 y N N Imp 
3* Resp 18 B F 10 +mod + 10 y N N Imp 
4 Surg 50 C M 3 +mild + 3 N y y Died 
5* Surg 82 w F 4 +mild - 4 y N y Died 
6* surg 20 B M 10 +mod - 4 y N y Imp 
7* Surg 71 w M 7 +mod - 12 y y y Imp 
8* surg 46 w F 4 +mod - 3 y N y Same 
9* Surg 67 C F 5 +mod + 5 y N y Same 
10* Surg 32 B F 4 +mild + 21 N y N Same 
1::.* Surg 26 w M 6 - +severe 10 y y y Same 
12* Surg 33 B F 7 - +mod 6 y y y Imp 
13 Surg 49 C F 4 - +mild 3 N y y Worse 
14* Surg 47 C M 5 - +mild 3 y N y Imp 
15 Resp 60 w M 2 - +mild 4 N y N Died 
16* Surg 24 C M 2 - +mild 3 N y y Imp 
17 Resp 64 C M 2 - +mild 5 y N N Same 
18* Surg 52 C F 2 - +mod 6 y y y Same 
19* Surg 45 w M 2 - +mod 3 y y y Imp 
20* surg 67 C F - +mild 10 N y y Died 
21* Surg 75 C M - - 3 y y y Same 
22 Resp 40 w M 2 - - 4 N N N Died 
23 Resp 64 w M 2 - - 7 N N N Imp 
24 Resp 46 C M 2 - - 4 N y N Died 
25 Surg 67 w M 4 - - 3 N y y Same 
26 Resp 38 C F 8 - - 5 N N N Imp 
27 Surg 48 B M 2 - - 3 N y N Imp 
28 Resp 50 C F 4 - - 3 N N N Imp 
29 Surg 33 B M 3 - - 3 N N N Imp 
30 Surg 60 w M 2 - - 4 N N y Died 
31 Resp 47 w M 2 - - 35 N N N Same 
32 Resp 25 B M 2 - - 4 N N N Same 
33* Resp 60 B M 2 - - 5 N N N Imp 
34* Resp 55 B M 4 - - 9 N N y Imp 
35* Surg 45 w M 2 - - 5 N N N Imp 
36* Resp 28 C F 2 - - 56 N N N Same 
37* Resp 27 C F 7 - - 5 N N y Imp 
38 Surg 84 w M 3 - - 21 y N y Imp 
39* Resp 28 C M 4 - - 7 y N N Imp 
40* Surg 53 B M 5 - - 4 N N N Imp 
41* Resp 23 C M 4 - - 3 y N y Imp 
42 Surg 30 C F 2 - - 3 y N N Imp 
43* Surg 25 C M 4 - - 3 y y y Imp 
44 Surg 73 w M 4 - - 28 y y y Same 
45 Surg 29 C M 3 - - 12 y y N Imp 
46 Surg 30 B M 2 - - 42 y y y Imp 
47* Surg 58 B M 2 - - 21 N N N Imp 
48* Surg 65 w M 4 - - 14 y y y Imp 
Pt= patient, *=bacterial overgrowth test done, ICU= intensive care unit, Lngth BR= length of bowel 
rest, Diarr Bef = diarrhoea before feeding, Diarr Aft= diarrhoea after feeding, Days feeding= days on 
enteral feeding, M = male, F = female, W = white, C = coloured, B = black, surg = surgical intensive care, 
Resp= respiratory intensive care, amik = amikacin therapy, sucral = sucralfate therapy, abd. t = abdominal 
trauma, y = YES, N = NO, mod= moderate 
APPEND1X2 
DIAGNOSES AND CLINICAL CONDITION OF THE PATIENTS. 
PATIENT 1 
Leaking abdominal aortic aneurysm, duodenal ulcer. Previous Ca prostrate ( Right bilateral 
orchidectomy) and Ca ascending colon (Right hemi-colectomy). Patient admitted to intensive 
care after going into respiratory failure. Resistant Staphylococcus cultured from sputum. 
Medication: 
Clindomycin (600mg i.v, 8hrly), Amikacin (500mg i.v, bd), Pen G (5mU i.v, 6hrly), Flagyl (500mg 
i.v, 8hrly), Sucralfate (1g orally, 6hrly) 
PATIENT2 
Non-insulin dependant diabetes mellitus. Previous infarct, amputation of right toe. Now 
presented with infection and gas gangrene in foot and leg. Also septicaemic, bedridden and 
confused. 
Medication: 
Clindomycin (600mg i.v, 6hrly), Metronidazole (500mg i.v, 8hrly), Amikacin (250mg i.v, 12hrly), 
Actrapid (50u i.v). 
PATIENT 3 
Bronchiectasis, pneumonia, respiratory failure. Previous tuberculosis and 5 days post partum 
on admission. Septicaemic. 
Medication: 
Ampicillin (1g i.v, 6hrly), Amikacin (350mg i.v. bd), Flagyl (500mg i.v, 8hrly), Ventolin 1:4, 4hrly), 
Kloref (2 orally, bd), Prednisone (30mg orally, daily), Pipricillin (2g i.v, 6hrly), Aminophyllin 
(1 g/200ml i.v, 9ml/hr), Pyridoxine (50mg orally, daily), INH (300mg orally, daily), Metronidazole 
(500mg i.v, 6hrly). 
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PATIENT 4 
Bleeding oesophageal varices, ethanolic cirrhosis, hepatic encephalopathy. Ascites present. 
Patient pyrexial and in multiple organ failure 6 days after admission. Active treatment 
withdrawn. 
Medication: 
Lactulose (20ml orally, 8hrly), Aldactone (50mg orally, 12 hrly), Sucralfate {1g orally QID), 
Ampicillin {500mg i.v, 6hrly), Cefotaxime {1g i.v, 6hrly). 
PATIENT 5 
Ruptured abdominal aortic aneurysm. At operation, rupture into left colon, mesentery and 
sigmoid mesocolon. Patient developed collapse of left lung. Also hypertensive. 
Medication: 
Ventolin (1 :4 , 4hrly), Penicillin {2mU i.v, 6hrly), Amikacin (500mg i.v, pm), Morphine (5mg i.v, 
pm), Diazepam (5mg i.v, pm). 
PATIENT& 
Lacerated stomach due to stab wounds, hole in diaphragm, soiled abdomen. Emergency 
laparotomy. Respiratory failure. cardiac failure, right cerebral infarct. Hypertensive and in septic 
shock. 
Medication: 
Amikacin {500mg i.v, daily), Pen G (2 megaU i.v, 6hrly), Flagyl {1g i.v 12 hrly), Cloxacillin {2g i.v, 
6hrly). 
PATIENT7 
Ruptured abdominal aortic aneurysm. Retroperitoneal bleeder found and tied off. No previous 
medical problems. 
Medication: 
Pen G (2 megaU i.v, 6hrly), Amikacin {500mg i.v, 6hrly), Epanutin {300mg i.v, bd), Digoxin (o.25g 
i.v, daily), Sucralfate (1 g orally, 8hrly), Nystatin (1 ml orally, 6hrly). 
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PATIENT 8 
Bleeding oesophageal varices, chronic liver disease, malaena stools and vomiting, clinically 
jaundiced. 
Medication: 
Neomycin (1 g orally, 6hrly), Lactulose {20ml orally, 8hrly), Ranitidine (50mg i.v, 8hrly), PenG 
(2megaU i.v, 6hrly), Amikacin (500mg i.v, 12hrly), Flagyl (500mg i.v, 8hrly), Aldactone (200mg 
i.v, 12hrly), Clindomycin (600mg i.v, 8hrly), Lasix (10mg i.v, 6hrly). 
PATIENT9 
Respiratory arrest, cardiac arrest, bleeding gastric ulcer. Patient underwent Bilroth 1 
gastrectomy. 
Medication: 
PenG (5 megaU i.v, 6hrly), Morphine (10mg i.v, 4hrly), Amikacin (500mg i.v, bd), TNT 
(50mg/200ml i.v, 30dpm), Cloxacillin (1 g i.v, 6hrly). 
PATIENT 10 
Multiple fractures and head injury following motor accident. 
Medication: 
Penicillin (5megaU i.v, 6hrly), Sucralfate (1 g orally, 6hrly), Cloxacillin (2g i.v, 6hrly). 
PATIENT 11 
Wall fell on patient's chest. Left pneumothorax, left flank haematoma, left hemispherical infarct, 
liver damage, bowel ischaemia. 
Medication: 
Sucralfate (1g orally, 6hrly), Cloxacillin (2g i.v, 6hrly), Amikacin (500mg i.v, 12hrly), Morphine 
(50mg i.v, 2 hrly), Clindamycin (600mg i.v, 8hrly), Cefotaxime (1 g i.v, 6hrly), Lasix 20mg i.v, 
6hrly). 
PATIENT 12 
Acute haemorrhagic pancreatitis. Abortion at 24 weeks two weeks prior to admission. 
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Medication: 
Sucralfate (1g orally, 6hrly), Valium (5mg i.v, 4hrly), Amikacin (500mg i.v, 12hrly), Flagyl (500mg 
i.v, 8hrly), PenG (2 megaU i.v, 6hrly), Actrapid (sliding scale). 
PATIENT 13 
Patient involved in motor accident. Broken humerus, compound fracture of tibula/fibula, 
lacerated spleen (splenectomy), contused small bowel, large incisional hernia. Jaundiced. 
Developed abdominal abscess in intensive care just before going onto trial. 
Medication: 
PenG (5 megaU i.v, 6hrly), Morphine (2mg i.v, pm), Sucralfate (1 g orally, 6hrly). 
Patient 14 
Liver failure, bleeding oesophageal varices, portal hypertension, hepatic encephalopathy, 
ascites and cirrhosis. 
Medication: 
Lactulose {30ml orally, 8hrly), Neomycin (1 g orally, 8hrly), Penicillin (2 megaU i.v, 6hrly), 
Amikacin (500mg i.v, bd), Aldactone (50mg i.v, 6hrly). 
PATIENT 15 
Myelodysplastic syndrome. Respiratory failure secondary to klebsiella pneumonia. 
Medication: 
Flagyl (400mg orally, 8hrly), Mycostatin (4ml orally 4 hrly), Digoxin (0.25mg orally, 6hrly), 
Cefotaxime (1 g i.v, 6hrly), Sucralfate (2g orally, 12hrly). 
PATIENT 16 
Post MVA. Head injury, generalized brain swelling. Also episode of dark vomitus, query acute 
gastritis. 
Medication: 
Bactrim (1amp i.v, bd), Decadron (8mg i.v, 8hrly), Valium (5mg i.v, 6hrly), Morphine (5mg i.v, 
2hrly), Etomine (80mg i.v, 6hrly), Sucralfate (1 g orally, 6hrly). 
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PATIENT 17 
Known COAD. Steroid induced bronchospasms caused respiratory arrest and chest infection. 
Medication: 
Hydrocortisone (200mg i.v, 4hrly), Aminophyllin (250mg i.v, 6hrly), Amikacin (400mg i.v, bd), 
Penicillin (2megaU i.v, 6hrly), Potassium chloride (10ml orally, 6hrly), Ventolin (10mg/200ml i.v, 
daily), Monotard (Sunits bd). 
PATIENT 18 
Post MVA. Multiple trauma. Ruptured left hemidiaphragm, small retroperitoneal haematoma, 
lateral dislocation of the knee, respiratory distress, hypertensive. 
Medication: 
Morphine (5mg i.v, pm), Diazapam (5mg i.v, pm), Sucralfate (1 g orally, 6hrly), Penicillin 
(2macroU i.v, 6hrly), Amikacin (400mg i.v, bd). 
PATIENT 19 
Post MVA. Large left haemothorax, lung contusions, acute abdomen, haematuria, ruptured 
diaphragm, shattered spleen and some bowel in chest. Patient had two laparotomies and 
developed respiratory failure post-op. 
Medication: 
Morphine (Sg i.v, 2hrly), Valium (10g i.v, pm), Sucralfate (2g orally, 6hrly), Ventolin nebs (1 :4, 
pm), Cloxacillin (2g i.v, 6hrly), Epanutin (200mg i.v, 8hrly), Amikacin (500mg i.v, 12hrly), 
Aminophyllin (400mg i.v, 6hrly). 
PATIENT20 
Admitted one month previously. Gastric ulcer found. Developed respiratory distress in ward 
and G.I rebleed. Gastrectomy done. Patient to I.C.U. Became septicaemic, hyperglycaemic 
and developed respiratory distress. Patient also develped prolapsed pile and became 
jaundiced. When put onto trial patient was much improved. 
Medication: 
Sucralfate (1g orally, 6hrly), Flagyl (500mg i.v, 8hrly), Ventolin (1:4, 4hrly), Cefotaxime (1g i.v, 
6hrly), Amphotericin B (10mg i.v, 6hrly). 
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PATIENT21 
Abdominal aortic aneurysm. Adult respiratory distress syndrome. Patient sent to intensive care 
following prolonged procedure for repair of ruptured abdominal aortic aneurysm. Problems of 
hyperkalaemia and oliguria. Also bleeding from colic artery. Mild jaundice. Patient entered into 
trial 1 O days post-op. 
Medication: 
Amikacin (250mg i.v, bet), Flagyl (500mg i.v, 8hrly), PenG (2macroU i.v, 6hrly), Sucralfate (1 g 
orally, 6hrly), Vancomycin (1 g i.v, bet). 
PATIENT22 
Hodgkins lymphoma, progressive muscle weakness, respiratory failure, radiation pneumonitis. 
Patient received total body irradiation and given double dose by mistake. 
Medication: 
Prednisone (20mg oraly, daily), Erythromycin (500mg orally, 6hrly), lpradol (1 :4) 
PATIENT23 
Chronic obstructive airways disease, iron deficiency anaemia, recto-sigmoid polyp, chest 
infection. Patient admitted with swollen ankles and tight chest. Admitted to medical ward. 
Then developed severe respiratory distress and had to be intubated and ventilated. 
Medication: 
Bactrim (10mg i.v, bet), Ventolin (10mg i.v, daily), Hydrocortisone (200mg i.v, 4hrly), 
Aminophyllin (250mg i.v, 6hrly), Iron sulphate (200mg orally, tds), Ranitidine (50mg i.v, tds), 
Valium (10mg i.v, pm), Fentonyl (1amp i.v, pm), Moduretic (2 orally, daily). 
PATIENT24 
Patient admitted to trauma unit due to severe burns (16%) to face, scalp, chest and hand. Also 
large amounts of soot in nose and pharynx. Upper airways obstruction. 
Medication: 
Sucralfate (1 g orally, 6hrly), Penicillin (2macroUi.v, 6hrly), Ventolin (1 :4, 4hrly), Morphine (2mg 
i.v, pm), Valium (5 - 10mg i.v, pm). 
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PATIENT25 
Emergency surgery for ruptured abdominal aortic aneurysm. Known hypertensive. Patient 
became jaundiced and septicaemic and developed poor urine output. Patients conditioned had 
improved by the time he was started on this trial.. 
Medication: 
Cefotaxime (1 g i.v, 6hrly), Sucralfate (1 g orally, 6hrly). 
PATIENT26 
Patient was a known steroid dependant asthmatic. Admitted with bronchospasm which did not 
respond to pump. Severe asthma attack due to right upper lobe lung infection. 
Mediation: 
Prednisone (60mg orally, daily), Ranitidine (150mg orally, bd), Amoxyl (500mg orally, tds), 
Clindamycin (600mg i.v, 6hrly), Vancomycin (1g orally, 12 hrly), Salbutamol (10mg/1000ml, 
daily), Euphyllin retard (2,5 tabs bd). 
PATIENT27 
Patient referred from general medical ward with respiratory failure. Background history of PTB, 
COAD. 
Medication: 
Lasix (40mg i.v, bd), Hydrocortisone (100mg i.v, 4hrly), Spironolactone (5g orally, daily), PenG 
(2G=g i.v, 6hrly), lpradol (1:4, 6hrly), INH (500mg orally, daily), Sucralfate (1g orally, 6hrly), 
Ampicillin (500mg i.v, 6hrly). 
PATIENT28 
Patient was known to suffer from asthma and COAD. Admitted due to increasing shortness of 
breath and green sputum production. Condition deteriorated with cyanosis, wheeze. Patient 
also became pyrexial. 
Medication 
Aminophyllin (400mg i.v, 12hrly), Ventolin (1 :4 inhaled, 4hrly), Atropine (1 :4 inhaled, 4hrly), 
Hydrocortisone (200mg i.v, 4hrly), Ampicillin (500mg i.v, 6hrly), Ranitidine (50mg i.v, 8hrly). 
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PATIENT29 
Patient assaulted with a lead pipe. Fractured skull and mandible, chest complications, small 
pneumothorax. 
Medication: 
Morphine (20mg/200ml i.v, 5 drops/minute), PenG (2macroU i.v, 6hrly), Flagyl (500mg i.v, 
8hrly). 
PATIENT30 
Patient admitted for intensive care post surgery after removal of a septic bifemoral graft repair. 
Patient in septic shock, respiratory failure. 
Medication: 
Flagyl (500mg i.v, 8hrly), Penicillin (5macroU i.v, 6hrly), Valium (5g i.v, pm), Cloxacillin (1g i.v, 
6hrly), Morphine (5mg i.v, pm), Gentamycin (60mg i.v, 8hrly). 
PATIENT31 
Guillain-Barre syndrome, chronic schizophrenia. Patient developed weakness in hands and 
feet. Admitted with polyradiopathy. 
Medication: 
Stelazine (2 orally, bd), Benzhexol (2mg orally, bd), Amoxyl (500mg orally, tds). 
PATIENT32 
Known asthmatic. Admitted with severe respiratory distress due to bronchospasm. Also 
bradycardia, chest infection. Patient unconscious at the time of the trial. 
Medication: 
Flagyl (500mg i.v, 8hrly), Epanutin {100mg i.v, 8hrly), Euphyllin retard (2 tabs orally, 12hrly), 
Prednisone (40mg orally, daily). 
PATIENT33 
Post MVA. COAD, broken ribs, pulmonary contusion, complete collapse of left lung. 
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Medication: 
Aminophyllin (250mg i.v, 6hrly), Ventolin (1 :4, 4hrly), Ampicillin (1 g i.v, 6hrly), Morphine (5mg i.v, 
pm). 
PATIENT34 
Post MVA. Multiple trauma. Flail chest, contused lung, respiratory distress, lacerated scalp, 
haematuria, possible intra-abdominal bleed. 
Medication: 
Penicillin (2.5 macroU i.v, 6hrly), lpradol (1 :4, 12hrly), Panadeine (2 orally, 6hrly). 
PATIENT35 
Patient involved in motorcycle accident. Head injury, unconscious. Broken ribs and right femur. 
Medication: 
Penicillin (5macroU i.v, 6hrly), Valium (5mg i.v, 6hrly). 
PATIENT36 
Patient admitted to intensive care due to respiratory failure. Previously diagnosed tuberculosis. 
Patient could not keep T.B medicine down. Fainted and hit the back of her head. Left eye vision 
and limb movement began to deteriorate. Tentative diagnosis of Devick's syndrome. 
Medication: 
Medrol (1g i.v, daily), Rifampicin (450mg orally, daily), PZA (1g orally, daily), Pyridoxine (25mg 
orally, daily). 
PATIENT37 
MVA pedestrian. Deaf mute. Multiple trauma, right pneumothorax, laceration of liver, 
contusions of small bowel. Multiple broken bones. 
Medication: 
PenG (5macroU i.v, 6hrly), Cloxacillin (2g i.v, 6hrly), Ventolin (1 :4, 4hrly), Valium (5mg i.v, pm), 
Fetanyl (100mg i.v, daily). 
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PATIENT38 
Small bowel obstruction relieved by laparotomy 2 weeks prior to being admitted to intensive 
care. Patient developed streptococcal pneumonia, became pyrexial. Level of consciousness 
deteriorated. 
Medication: 
Digoxin (0.25mg i.v, daily), Actrapid (sliding scale), PenG (2megaU i.v, 6hrly), Clindamycin 
(600g i.v, 8hrly), lsordil (10mg orally, 6hrly), Phenytoin (100g i.v, tds), Cloxacillin (2g i.v, 6hrly), 
Amikacin (500mg i.v, bd). 
PATIENT39 
Kartagener's syndrome, bronchiectasis, septicaemia. Patient required intubation and 
ventilation. 
Medication: 
Penicillin (2macrou i.v, 6hrly), Amikacin (400mg i.v, 12hrly), Ventolin (1 :4. 4hrly), Flagyl (500mg 
i.v, 8hrly), Pipericillin (1 g i.v, 6hrly). 
PATIENT40 
Abscess on left buttock. Previous operations for abcesses and anorectal fistulae. Pyrexial, 
septicaemic after operation to remove abcess. 
Medication: 
Penicillin (2macroU i.v, 6hrly), Flagyl (500mg i.v, 8hrly), Ventolin (1 :4, 6hrly), Valium (10mg i.v, 
6hrly), Morphine (5mg i.v, 6hrly), PenG (5macroU i.v, 6hry), Aminophyllin (250mg/200ml i.v, 
6hrly). 
PATIENT 41 
Multiple stabs to chest, bilateral pneumothorax, right surgical emphysema, wheezing. 
Medication: 




Post MVA. ARDS, fat embolus, broken pelvis, broken femur, ruptured bladder. Admitted to ICU 
because of developement of fat embolus, ARDS. 
Medication: 
Morphine (10mg i.m, 6hrly), Penicillin (5macroU, 6hrly), Amikacin (500mg i.v, bd), Flagyl (1g 
orally, 8hrly). 
PATIENT43 
Post MVA. Multiple trauma, scalp laceration, broken pelvis, retroperitoneal haematoma. 
Medication: 
PenG (2macroU, i.v, 6hrly), Sucralfate (1g orally, 6hrly), Amikacin (500mg i.v, 12hrly), Ampicillin 
(1g i.v, 6hrly). 
PATIENT 44 
Hepatic carcinoma. Previous prostatectomy. Admitted after respiratory arrest, bleeding in 
abdomen. Bleeding liver tumour found on laparotomy. 
Medication: 
Sucralfate (1 g orally, 6hrly), Flagyl (500mg i.v, Bhrly), PenG (2macroU i.v, 6hrly), Amikacin (500g 
i.v, 12hrly). 
PATIENT45 
Stab to left side of neck. Major venous injury, tracheal injury. Hypoxia, wound sepsis. 
Medication: 
Amikacin (500mg i.v, 12hrly), Cloxacillin (2g i.v, 6hrly), Flagyl (500mg i.v, 8hrly), Sucralfate (1 g 
orally, Bhrly). 
PATIENT 46 
Post MVA. Head injury, blunt injury to chest, unconscious, periphrenic haematoma. 
Medication: 
Morphine (50mg/200ml i.v), Sucralfate (1g orally, 6hrly), Amikacin (500g i.v, 12hrly), PenG 
(2megaU i.v, 6hrly). 
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PATIENT 47 
Multiple injuries due to heavy fall. Retroperitoneal haematoma, both legs broken, possible head 
injury. 
Medication: 
Cloxacillin (1g i.v, 6hrly), Morphine (10mg i.v, pm), Valium (10mg i.v, 2hrly). 
PATIENT 48 
Ulcerative colitis since 1964. Total colectomy and ileostomy done in 1986. Admitted to 
intensive care with bowel distension following revision of ileostomy. 30cm of ischaemic bowel 
resected, multiple adhesions. 
Medication: 
Sucralfate (1 g orally, 6hrly), Amikacin (400mg i.v, bd), Ventolin (0.25mg i.v, daily), Thioridazine 
(25mg orally, daily). 
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